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The Courage Trial: A Phase II Randomized Clinical Trial to Evaluate the
Dose-Response Effects of Exercise on Prognostic Biomarkers Among
Colon Cancer Survivors
Abstract
Observational epidemiologic data suggest that participation in physical activity after a diagnosis of colon
cancer reduces the risk of cancer recurrence, cancer-specific mortality, and all-cause mortality. However, the
biologic mechanisms that mediate the relationship between physical activity and disease outcomes among
colon cancer survivors have not been characterized. Excess visceral adipose tissue and hyperinsulinemia
promote the growth and progression of existing micro-metastases and the development of new distant
metastases. Exercise reduces visceral adipose tissue and hyperinsulinemia among non-diabetic persons with
obesity. However, it is unknown if exercise alters visceral adipose tissue and hyperinsulinemia among colon
cancer survivors. We conducted a phase II, randomized, six month, dose-response exercise trial that compared
150 min•wk-1 or 300 min•wk-1 of moderate-intensity aerobic exercise to a usual care control group among 39
colon cancer survivors. We examined the efficacy of exercise to reduce visceral adipose tissue and fasting
insulin. To understand the generalizability of this trial we examined demographic, clinical, and geographic
characteristics of trial participants as compared to the cancer registry population from which they were
recruited. Mean age was 56.5±10.0 years, 51% had stage III disease, 72% were treated with chemotherapy, and
the mean time since finishing treatment was 10.9±6.1 months. Over six months, the low-dose group
completed 141.5±9.9 min∙wk-1 of aerobic exercise, and the high-dose group completed 247.2±10.7 min∙wk-1
of aerobic exercise. VAT increased 5.31±4.80 cm2 in the control group, and decreased 4.13±4.53 in the low-
dose group, and 8.27±4.89 in the high-dose group (linear Ptrend=0.008). Fasting insulin concentrations
decreased 7.4±9.4 pmol/L in the control group, 28.0±8.3 pmol/L in the low-dose group, and 20.7±9.3 pmol/
L in the high-dose group (nonlinear Ptrend=0.042). Colon cancer survivors screened for eligibility and
enrolled in the study were younger (screening P<0.001, enrollment P=0.007) and more likely to have been
treated with chemotherapy (screening P<0.001, enrollment P=0.006) than the population from which they
were recruited. The findings from this trial inform key design aspects for future phase II and phase III
randomized controlled trials among colon cancer survivors.
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ABSTRACT 
 
THE COURAGE TRIAL: A PHASE II RANDOMIZED CLINICAL TRIAL TO EVALUATE 
THE DOSE-RESPONSE EFFECTS OF EXERCISE ON PROGNOSTIC BIOMARKERS 
AMONG COLON CANCER SURVIVORS 
 
Justin C. Brown 
 
Kathryn H. Schmitz 
 
Observational epidemiologic data suggest that participation in physical activity after a 
diagnosis of colon cancer reduces the risk of cancer recurrence, cancer-specific 
mortality, and all-cause mortality.  However, the biologic mechanisms that mediate the 
relationship between physical activity and disease outcomes among colon cancer 
survivors have not been characterized.  Excess visceral adipose tissue and 
hyperinsulinemia promote the growth and progression of existing micro-metastases and 
the development of new distant metastases.  Exercise reduces visceral adipose tissue 
and hyperinsulinemia among non-diabetic persons with obesity.  However, it is unknown 
if exercise alters visceral adipose tissue and hyperinsulinemia among colon cancer 
survivors.  We conducted a phase II, randomized, six month, dose-response exercise 
trial that compared 150 min·wk-1 or 300 min·wk-1 of moderate-intensity aerobic exercise 
to a usual care control group among 39 colon cancer survivors.  We examined the 
efficacy of exercise to reduce visceral adipose tissue and fasting insulin.  To understand 
the generalizability of this trial we examined demographic, clinical, and geographic 
characteristics of trial participants as compared to the cancer registry population from 
which they were recruited.  Mean age was 56.5±10.0 years, 51% had stage III disease, 
72% were treated with chemotherapy, and the mean time since finishing treatment was 
10.9±6.1 months.  Over six months, the low-dose group completed 141.5±9.9 min·wk-1 of 
aerobic exercise, and the high-dose group completed 247.2±10.7 min·wk-1 of aerobic 
vii 
exercise.  VAT increased 5.31±4.80 cm2 in the control group, and decreased 4.13±4.53 
in the low-dose group, and 8.27±4.89 in the high-dose group (linear Ptrend=0.008).  
Fasting insulin concentrations decreased 7.4±9.4 pmol/L in the control group, 28.0±8.3 
pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group (nonlinear 
Ptrend=0.042).  Colon cancer survivors screened for eligibility and enrolled in the study 
were younger (screening P<0.001, enrollment P=0.007) and more likely to have been 
treated with chemotherapy (screening P<0.001, enrollment P=0.006) than the population 
from which they were recruited. The findings from this trial inform key design aspects for 
future phase II and phase III randomized controlled trials among colon cancer survivors.         
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CHAPTER 1.  INTRODUCTION  
Prologue 
Each year 83,000 people are diagnosed with stage I-III colon cancer in the United States 
[Siegel et al, 2015].  Despite being cured of their primary cancer, 25-50% will experience 
recurrent disease within three years of diagnosis, and 91% of those with recurrent 
disease die within five years after their initial diagnosis [Sargent et al, 2005].  Colon 
cancer survivors consistently cite fear of recurrent disease as their chief health concern 
[Baker et al, 2005].  Consequently, physicians often field questions such as “Should I 
exercise?  Should I lose weight?  What will improve my chances?”  Unfortunately, colon 
cancer survivors soon learn there are few definitive answers to such basic inquiries.  
Understanding how modifiable lifestyle behaviors such as physical activity or exercise 
may affect disease outcomes will advance the management of colon cancer and 
empower patients with practical solutions to improve their outcomes. 
Observational studies indicate that participation in physical activity or exercise after a 
diagnosis of colon cancer is associated with a 50% reduction in the risk of cancer 
recurrence and mortality [Meyerhardt et al, 2006, Meyerhardt et al, 2006].  Physical 
activity is associated with improved disease outcomes in a dose-response fashion, such 
that increasing volumes of physical activity are associated with more favorable outcomes 
[Schmid and Leitzmann, 2014].  However, the biologic or biobehavioral pathways 
through which physical activity or exercise may favorably alter disease outcomes among 
colon cancer survivors have not been elucidated.  Two pathways hypothesized to 
mediate the relationship between exercise and disease outcomes among colon cancer 
survivors include alterations in body composition and alterations in insulin metabolism 
and glucose homeostasis.  This study will help to clarify how exercise may alter 
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pathways hypothesized to influence disease outcomes and the sensitivity of such 
pathways to respond to different doses of exercise.  We will also examine the 
generalizability of these findings to the broader population of colon cancer survivors.  
The data gathered from this study will improve the specificity of exercise prescriptions 
provided to colon cancer survivors, strengthen the rationale that a causal relationship 
exists between exercise and disease outcomes, and help to refine key design aspects 
for future randomized trials in this population. 
Colon Cancer Treatment and Prognosis 
Each year, 103,000 people are diagnosed with colon cancer in the United States [Siegel 
et al, 2015].  Among those diagnosed, 39% will have stage I-II colon cancer (localized to 
the primary site), 36% will have stage III colon cancer (spread to regional lymph nodes), 
and 20% will have stage IV colon cancer (distant metastatic disease) [DeSantis et al, 
2014, Siegel et al, 2014].  For patients with metastatic colon cancer, the five-year 
survival rate is 10%.  In contrast, five-year survival rates for stage I-II and stage III colon 
cancer are 90% and 70%, respectively [DeSantis et al, 2014].  Surgery is the primary 
treatment modality for stage I-III colon cancer, with a curative resection occurring in 80–
85% of patients.  Adjuvant chemotherapy is used to lower the risk of recurrence in 
patients with stage II disease who have high-risk features (such as T4 lesions, 
inadequate lymph node resection, poorly differentiated histology, presence of 
lymphovascular invasion, and bowel obstruction or perforation) and in patients with 
stage III disease [André et al, 2004, Quasar Collaborative Group, 2007].  Despite 
surgical resection, either alone or in combination with adjuvant chemotherapy, five-year 
recurrence rates for stage I, II, and III colon cancer are 10%, 20%, and 30-50%, 
respectively [André et al, 2004, Clinical Outcomes of Surgical Therapy Study Group, 
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2004, Quasar Collaborative Group, 2007].  Although many patients may be cured with 
standard therapy, there remains a critical need to identify additional adjuvant therapies 
to reduce recurrent disease in this population. 
Colon Cancer Outcomes: Recurrence and Metastasis  
The high rate of recurrent and metastatic disease is a critical barrier to the health and 
longevity of colon cancer survivorship.  Cancer recurrence and metastasis are the 
leading causes of morbidity and mortality in colon cancer, marking the transition from 
localized, potentially curable to disseminated, usually incurable disease [Renfro et al, 
2015].  Colon cancer recurrence is often characterized by loco-regional relapse and/or 
distant metastasis to the liver or lung [Tsikitis et al, 2009].  Eighty percent of recurrences 
occur in the first three years after treatment, and 91% of those with recurrent disease die 
within five years after their initial diagnosis [Sargent et al, 2005].  The timing and pattern 
of colon cancer recurrence is consistent with the hypothesis that colon cancer survivors 
have residual local and distant micro-metastases remaining at the completion of curative 
therapy [Chambers et al, 2002, Meyerhardt et al, 2010], which cannot be identified using 
contemporary surveillance methods such as computed tomography (CT) and serum 
levels of carcinoembryonic antigen (CEA) [Primrose et al, 2014]. 
Interventions that attenuate host factors that are hypothesized to promote the 
progression of these residual local and distant micro-metastases may improve long-term 
outcomes among colon cancer survivors.  Two such host factors include body 
composition, specifically excess visceral adipose tissue (VAT), and metabolic factors, 
specifically insulin [Schwartz and Yehuda-Shnaidman, 2014, Vigneri et al, 2015].  The 
prevention of cancer recurrence and metastasis are key health priorities for colon cancer 
survivors [Baker et al, 2005].  Developing interventions that colon cancer survivors can 
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accomplish autonomously, such as modification of lifestyle with exercise, will equip colon 
cancer survivors with practical solutions to improve their outcomes. 
Colon Cancer Outcomes and Visceral Adipose Tissue  
The two main compartments in which adipose tissue are stored include: 1) 
subcutaneous adipose tissue (SAT) and 2) VAT [Ibrahim, 2010].  SAT represents a 
usual physiologic buffer to store excess energy.  When the storage capacity of SAT is 
exceeded, VAT is accrued.  Accordingly, 80–90% of all body fat is SAT, and the 
remaining 10–20% is VAT [Tchernof and Despres, 2013].  The adipocytes that constitute 
VAT are physiologically and pathologically distinct from SAT [Ibrahim, 2010, Tchernof 
and Despres, 2013].  The adipocytes of VAT are more deleterious to health than the 
adipocytes of SAT, due to their metabolic secretion of bioactive compounds such as 
adipokines, cytokines, hormone-like factors, and other metabolites [Ahima and Flier, 
2000, Balistreri et al, 2010].  The deleterious metabolic activity of VAT, coupled with 
anatomic proximity to vital organs, and direct drainage into portal venous vasculature (a 
key route of many colon cancer metastases), manifests as a pro-tumorigenic milieu 
(Figure 1.1) [Doyle et al, 2012]. 
Excess VAT independently predicts poor colon cancer outcomes.  Seven observational 
epidemiologic studies have examined the relationship between VAT and colon cancer 
outcomes.  Five studies have quantified VAT using CT imaging [Ballian et al, 2012, Guiu 
et al, 2010, Lee et al, 2015, Moon et al, 2008, Rickles et al, 2013], and two studies have 
quantified VAT using waist circumference as an anthropometric proxy [Haydon et al, 
2006a, Prizment et al, 2010].  All seven of these studies concluded that higher levels of 
VAT are associated with poorer colon cancer outcomes such as disease-free survival, 
cancer-specific mortality, and all-cause mortality.  For example, among 62 colon cancer 
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survivors, above-median values of VAT were associated with four-fold increase in the 
risk of disease recurrence or mortality over five years [Lee et al, 2015].  Among 526 
colon cancer survivors, each 10-centimeter increase in waist circumference is 
associated with a 20% increase in the risk of colon cancer-specific mortality [Haydon et 
al, 2006a].  In addition, excess VAT is a strong independent predictor of all-cause 
mortality among older adults without a history of cancer.  Among 1,089 men and women 
aged 18–84, each 70.1 cm2 (standard deviation) increase in VAT was associated with a 
74% increase in the risk of all-cause mortality, independent of age, smoking status, and 
cardiovascular disease [Katzmarzyk et al, 2012].  The relationship between VAT and 
mortality is j-shaped, such that as VAT increases, the risk of mortality increases 
exponentially [Kuk et al, 2006]. 
Body mass index (BMI), defined as weight (in kilograms) divided by height (in meters) 
squared (kg/m2), is a widely used metric to quantify body composition.  Elevated BMI is 
associated with the development of incident colon cancer [Larsson and Wolk, 2007], 
however several studies have concluded that BMI does not consistently influence colon 
cancer outcomes after diagnosis [Vrieling and Kampman, 2010].  For example, among 
1,053 stage III colon cancer survivors, greater BMI at diagnosis was not associated with 
recurrence (Ptrend=0.86), disease-free survival (Ptrend=0.65), or all-cause mortality 
(Ptrend=0.63) [Meyerhardt et al, 2008].  These findings are in contrast to the consistent 
deleterious impact of VAT on colon cancer outcomes, as described above.  BMI and 
VAT are poorly correlated [Ballian et al, 2012]; for example, a patient may have a normal 
weight BMI, but have pathogenic levels of VAT, or vice-versa (Figure 1.2).  BMI as a 
measure of adiposity assumes that fat tissue is distributed uniformly across the body, 
ignoring the known heterogeneity of regional deposition of adiposity [Tchernof and 
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Despres, 2013].  There exists substantial inter-individual variation between BMI and 
VAT. For example at a given BMI (30.0 kg/m2), VAT may vary by as much as 40% 
[Després, 2011].  Among colon cancer survivors, BMI accounts for only 30.4% of the 
variability in VAT [Rickles et al, 2013].  Thus, the location of adiposity may be more 
influential on colon cancer outcomes than the quantity of total-body adiposity (i.e, VAT 
may be a better marker of recurrence risk than BMI).  Together, these observations 
support that hypothesis that VAT is a metabolically active tissue that lends rise to 
deleterious colon cancer outcomes [Doyle et al, 2012].  VAT is associated with insulin 
resistance and resultant hyperinsulinemia among colon cancer survivors (r=0.519; 
P<0.001) [Jiang et al, 2014], which is implicated in the progression of recurrent and 
metastatic colon cancer [Vigneri et al, 2015]. 
Colon Cancer Outcomes and Hyperinsulinemia  
Hyperinsulinemia is characterized by an elevated concentration of insulin and 
exaggerated insulin response to increases in glucose concentration [Shanik et al, 2008].  
The adipocytes of VAT are more insulin-resistant than the adipocytes of SAT [Ibrahim, 
2010].  VAT is positively associated with fasting insulin [Seidell et al, 1990], and 
accounts for 18–40% of the variability in fasting insulin [Colman et al, 1995].  Each 10-
cm2 increase in VAT area is associated with a 0.46 μU/mL increase in fasting insulin 
[Goodpaster et al, 2003].  VAT is an independent predictor of insulin sensitivity, a 
measure of how efficiently insulin acts to lower blood glucose [Racette et al, 2006].  The 
relationship between VAT and insulin is important because colon cancer cells have 
insulin and insulin-like growth factor-I (IGF-I) receptors on their surface [Belfiore and 
Malaguarnera, 2011].  Insulin and IGF-I promote colon cancer cell proliferation and 
inhibit apoptosis [Koenuma et al, 1989], thereby increasing the aggressiveness of the 
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tumor phenotype [Vigneri et al, 2015].  In vitro studies demonstrate the state of 
hyperinsulinemia increases colon cancer cell resistance to 5-fluorouracil [Chen et al, 
2011b] and oxaliplatin chemotherapy [Chen et al, 2011a, Volkova et al, 2014].  
Preclinical models demonstrate that exposure to insulin promotes colonic tumor 
multiplicity [Tran et al, 1996]. 
Colon cancer survivors have fasting insulin levels that are 58% higher than age- and 
sex-matched controls without a history of colon cancer [Jiang et al, 2014].  
Hyperinsulinemia is often observed among people diagnosed with early stage type 2 
diabetes mellitus (T2DM).  Colon cancer survivors with T2DM have significantly worse 
prognosis than those without T2DM [Dehal et al, 2012, Jeon et al, 2013, Luo et al, 2014, 
Meyerhardt et al, 2003].  For example, among 3,759 stage II/III colon cancer survivors, 
those with T2DM had shorter five-year disease-free survival (48% vs. 59%), and shorter 
five-year overall survival (57% vs 66%) [Meyerhardt et al, 2003].  Markers of insulin 
secretion, such as C-peptide, are associated with a two-fold increase in the risk of death 
among men and women diagnosed with colon cancer [Wolpin et al, 2009].  
Hyperinsulinemia also promotes IGF-I biosynthesis, which inhibits production of insulin-
like growth factor binding protein (IGFBP)-3 [Sandhu et al, 2002].  Low levels of IGFBP-3 
are associated with a higher risk of death among non-metastatic colon cancer survivors 
[Haydon et al, 2006b, Wolpin et al, 2009].  Together, this evidence which spans from in 
vivo models to human observational studies, supports the hypothesis that 
hyperinsulinemia is associated with recurrence and metastasis among colon cancer 
survivors.  The relationship between VAT and hyperinsulinemia yields a pro-tumorigenic 
environment which may facilitate the progression of recurrent and metastatic disease 
among colon cancer survivors [Doyle et al, 2012].  Interventions that reduce VAT and/or 
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reduce hyperinsulinemia/insulin resistance may therefore have considerable impact on 
understanding colon cancer biology and improving the longevity of colon cancer 
survivorship. 
Mechanisms of VAT and Insulin Relevant to Colon Cancer Outcomes 
Though not completely elucidated, the PI3K-Akt-mTOR signaling pathway is a point of 
convergence that links both excess VAT and hyperinsulinemia to poor colon cancer 
outcomes [Huang and Chen, 2009, Weijenberg et al, 2013].  The PI3K-Akt-mTOR 
pathway is often hyper-activated in colon cancer [Wang and Zhang, 2014], and inhibition 
of this pathway has been considered a therapeutic target [Huang and Chen, 2009].  
mTOR is activated by Akt, inhibited by AMPK, and the activation of mTOR regulates cell 
survival, proliferation, and growth.  mTOR expression in colonic tumor tissue increases 
with disease stage, lymph node metastasis, and lymphovascular invasion [AlQurashi et 
al, 2013].  Activation of the PI3K-Akt-mTOR pathway is associated with the growth and 
progression of colon cancer metastases [Gulhati et al, 2011].  Patients whose tumors 
express mTOR tend to have lower median survival rates than patients whose tumors do 
not express mTOR (43 v 60 months, respectively; P=0.06) [AlQurashi et al, 2013].  
mTOR is sensitive to signals that reflect the nutritional and energetic states of the 
cellular environment.  In cellular environments with energy surplus, such as that with 
excess VAT, hyperinsulinemia, and IGF-1, mTOR is activated via PI3K-Akt signaling 
[McCurdy and Klemm, 2013].  This activation creates a competitive growth advantage 
for cancer cells, and promotes metastatic potential and chemotherapy resistance [Porta 
et al, 2014].  Conversely, in states of energy depletion, such as that required for 
exercise, mTOR is inhibited via AMPK [Chen et al, 2003].  Favorably altering the 
energetic states of the cellular environment by reducing excess VAT, hyperinsulinemia, 
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and IGF-1 may down-regulate the PI3K-Akt-mTOR pathway.  In a preclinical model, 
silencing of mTOR inhibited the growth of colon cancer metastases and induced cell-
cycle arrest and apoptosis [Zhang et al, 2009].  Considerable evidence has accumulated 
that implicates the PI3K-Akt-mTOR pathway in mediating the effects of excess VAT and 
hyperinsulinemia on colon cancer outcomes [Huang and Chen, 2009, Weijenberg et al, 
2013]. 
Colon Cancer Outcomes and Exercise or Physical Activity  
Physical activity or exercise is a modifiable lifestyle behavior that is associated with 
disease outcomes among colon cancer survivors.  Among 832 stage III colon cancer 
survivors, participation in physical activity after diagnosis was associated with a 45% 
improvement in disease-free survival (defined as cancer recurrence or death from any 
cause), and a 63% improvement in overall mortality [Meyerhardt et al, 2006].  This 
observation has been replicated in multiple cohorts of men [Campbell et al, 2013, 
Meyerhardt et al, 2009] and women [Campbell et al, 2013, Kuiper et al, 2012, 
Meyerhardt et al, 2006], and is independent of known demographic, clinico-pathologic, 
and treatment-related prognostic factors [Campbell et al, 2013, Kuiper et al, 2012, 
Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009]. 
A consistent finding in all of these cohort studies is that post-diagnosis physical activity is 
associated with disease outcomes in a dose-response fashion, such that larger doses of 
physical activity or exercise, up to approximately 300 minutes per week (min·wk-1), are 
associated with more favorable disease outcomes [Campbell et al, 2013, Kuiper et al, 
2012, Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009].  The 
relationship between physical activity volume and colon cancer outcomes has been 
depicted as a linear or quadratic pattern using spline models (Figure 1.3) [Meyerhardt et 
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al, 2006, Meyerhardt et al, 2009].  The splines suggest 225 min·wk-1 may be the 
minimum threshold necessary to improve colon cancer outcomes, however, outcomes 
continue to improve beyond 225 min·wk-1, suggesting that larger doses up to 300 
min·wk-1 may provide favorable disease-specific health benefits to colon cancer 
survivors.  This dose-response pattern has been confirmed in several meta-analyses 
[Des Guetz et al, 2013, Je et al, 2013, Schmid and Leitzmann, 2014].  However, the 
dose-response effects of exercise have not been studied among colon cancer survivors. 
Interestingly, levels of physical activity before diagnosis of colon cancer are not 
associated with colon cancer-specific mortality [Haydon et al, 2006a, Kuiper et al, 2012, 
Meyerhardt et al, 2006, Pelser et al, 2014].  This suggests the biologic or biobehavioral 
pathways through which physical activity reduces the primary development of colon 
cancer may differ from that of the prevention of recurrence and metastases, yielding 
greater focus upon the pro-tumorigenic milieu created by excess VAT and 
hyperinsulinemia [Doyle et al, 2012, Quadrilatero and Hoffman-Goetz, 2003, Vigneri et 
al, 2015].  The importance of the PI3K-Akt-mTOR pathway (as described earlier) is 
supported by observations that examine the impact of molecular marker expression as 
modifiers of the relationship between physical activity and colon cancer-specific death.  
Among colon cancer survivors whose tumor is PI3KCA wild-type, participation in 
physical activity is associated with a lower risk of colon cancer-specific death, whereas 
colon cancer survivors whose tumor harbors a PI3KCA mutation do not reap any cancer 
specific-survival benefit from physical activity [Meyerhardt et al, 2009].  The PI3KCA 
mutation allows the PI3K-Akt-mTOR pathway to signal without regulation from the 
cellular environment.  Consequently, altering states of energy balance (via exercise or 
other interventions) do not influence cell survival, proliferation, and growth.  Furthermore, 
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the PI3K-Akt-mTOR pathway regulates p27 expression, a cyclin-dependent kinase 
inhibitor that controls cell cycle progression.  Among colon cancer survivors whose 
tumors express p27, participation in physical activity is associated with a lower risk of 
colon cancer-specific death, whereas colon cancer survivors whose tumors do not 
express p27 do not reap benefit from physical activity [Meyerhardt et al, 2009].  
Together, these data provide further evidence that suggest the PI3K-Akt-mTOR pathway 
may have an important intercellular role in mediating the impact of excess VAT and 
hyperinsulinemia on colon cancer outcomes. 
The American College of Sports Medicine (ACSM), the American Cancer Society (ACS), 
and the National Comprehensive Cancer Network (NNCN) guidelines for cancer 
survivors recommend 150 min·wk-1 of moderate-intensity physical activity [National 
Comprehensive Cancer network, 2013, Rock et al, 2012, Schmitz et al, 2010].  This 
recommendation is inconsistent with the dose of physical activity necessary to improve 
disease outcomes in colon cancer survivors, as suggested by the epidemiologic 
literature.  Several reviews, including the ACSM statement for exercise among cancer 
survivors, have called for more research to empirically investigate the dose-response 
effects of exercise among cancer survivors [Brown et al, 2012b, Schmitz et al, 2010]. 
Exercise and Visceral Adipose Tissue  
Exercise is an efficacious modality to reduce excess VAT.  The “Studies of a Targeted 
Risk Reduction Intervention through Defined Exercise” (STRRIDE) trial [Kraus et al, 
2001], established the dose-response effects of exercise on VAT [Slentz et al, 2005, 
Slentz et al, 2004].  The STRRIDE study was a four-arm randomized controlled trial that 
compared three-doses of exercise to a control group for six months among 330 men and 
women who were overweight or obese with mild to moderate lipid abnormalities [Kraus 
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et al, 2001].  The STRRIDE study demonstrated a significant dose-response reduction in 
VAT, quantified using computed tomography (Ptrend<0.001; Figure 1.4) and waist 
circumference (Ptrend<0.001) [Slentz et al, 2005, Slentz et al, 2009, Slentz et al, 2004].  
The dose-response effects of exercise on VAT have been replicated among adults with 
the metabolic syndrome [Dutheil et al, 2013], and in meta-analyses of randomized 
exercise trial using weighted regression models [Ohkawara et al, 2007, Vissers et al, 
2013].  However, no study has examined the dose-response effects of exercise on VAT 
among colon cancer survivors. 
Exercise and Hyperinsulinemia  
Exercise significantly reduces fasting insulin levels in dose-response fashion 
[Friedenreich et al, 2011, Heydari et al, 2012, Houmard et al, 2004].  The STRRIDE 
study demonstrated a significant reduction in fasting insulin (P<0.001), and significant 
improvement in insulin sensitivity quantified using an intravenous glucose tolerance test 
(P<0.05) [Houmard et al, 2004].  These findings have been corroborated in a post-hoc 
analysis of a two-group randomized exercise study among overweight or obese post-
menopausal women [Friedenreich et al, 2011].  Exercise-induced improvements in VAT 
are associated with reductions in insulin resistance [O'Leary et al, 2006, Slentz et al, 
2005]. 
Characterizing Eligibility Screening and Enrollment of Clinical Trials  
Randomized clinical trials (RCTs) are considered the gold-standard study design to 
quantify the efficacy of an intervention [Piantadosi, 2005].  Validity is commonly cited as 
the primary reason why RCTs are the gold standard study design.  There are two forms 
of validity: internal validity and external validity.  Internal validity relates to whether the 
comparison of treatments is likely to be unbiased and un-confounded by external factors.  
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External validity, also known as generalizability, relates to whether the study results can 
be extended to the majority of patients for whom the results of the study may apply.  
RCTs are frequently designed in such a way that maximizes internal validity, 
subsequently reducing external validity [Gross et al, 2002, Wright et al, 2006].  Lack of 
external validity is a frequent criticism of RCTs, because patients enrolled in RCTs may 
differ from the general patient population with respect to demographic, clinical, and 
geographical characteristics such as age, sex, race, disease stage, and place of 
residence [Rothwell, 2005, Unger et al, 2014].  The enrollment process of RCTs has 
been presented in a conceptual framework by Gross et al. in “who are these patients 
and how did they get here?” [Gross et al, 2002].  This conceptual framework depicts flow 
of potential study participants through three distinct stages of recruitment (Figure 1.5).  
In stage one, investigators approach persons who are thought to represent a random 
sample of the underlying target population.  In stage two, persons who are approached 
and interested in participating in the RCT are screened to determine eligibility.  In stage 
three, persons who are interested in participating and are determined to be eligible are 
offered an opportunity to enroll in the RCT.  In each of these distinct stages of RCT 
enrollment, it is plausible that persons who proceed to the next stage represent a distinct 
subset of the population from which they were sampled (i.e., the target population).  For 
example, persons screened in stage two may differ demographically, clinically, or 
geographically, relative to persons identified in stage one [Rothwell, 2005].  Furthermore, 
persons enrolled in stage three, may also differ demographically, clinically, or 
geographically, compared to persons identified in stage one [Rothwell, 2005].  
Systematic differences in characteristics among persons in each of these stages may 
lead to selection bias that reduces the representativeness of RCT participants from the 
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underlying target population.  This lack of representativeness consequently reduces the 
external validity of the RCT. 
Lack of external validity in RCTs is hypothesized to partially explain the underuse of 
efficacious interventions in clinical practice despite recommendations for their use in 
clinical practice guidelines [Rothwell, 2005].  For example, the ACSM, ACS, and NCCN 
recommend that healthcare providers prescribe exercise to all colon cancer survivors 
[National Comprehensive Cancer network, 2013, Rock et al, 2012, Schmitz et al, 2010].  
However only 16.3% of colon cancer survivors are prescribed exercise by their 
healthcare provider, compared to 26.9% of matched adults without a history of cancer 
(P=0.003) [Sabatino et al, 2007].  Survivors of breast, prostate, cervical, and uterine 
cancer are prescribed exercise by their healthcare provider at rates similar to matched 
adults without a history of cancer.  These data indicate that healthcare providers may be 
particularly reluctant to prescribe exercise to colon cancer survivors [Brown and Schmitz, 
2014a]. 
To promote the prescription of exercise to colon cancer survivors in clinical practice, 
RCTs of exercise need to systematically characterize how colon cancer survivors who 
participate in an exercise RCT differ from those who do not participate.  To date, few 
exercise RCTs have characterized these differences.  Characterizing these differences 
would fill an evidence gap that may begin to solve several problems for healthcare 
providers who are being asked to prescribe exercise and study investigators who are 
generating data to support the prescription of exercise.  First, healthcare providers would 
have evidence to understand how colon cancer survivors who participate in an exercise 
RCT may differ from patients who receive care in their clinical practice.  Second, study 
investigators would be able to identify colon cancer survivor subgroups that may be less 
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likely to participate in an exercise RCT.  These subgroups can subsequently become the 
focus of targeted and tailored recruitment efforts to improve RCT participation and 
generalizability.  Characterizing how RCT participants differ from the population will also 
provide investigators evidence to empirically describe the generalizability of their trial.  
Filling this evidence gap may help to promote exercise as a standard component of 
colon cancer care and improve clinical trial methodology among colon cancer survivors 
[Brown and Schmitz, 2014a]. 
Study Design 
Together, this evidence formed the basis for the COURAGE trial.  The COURAGE trial was a 
National Cancer Institute (NCI) sponsored, phase II, randomized, dose-response 
exercise trial of two distinct doses of moderate-intensity aerobic exercise compared to a 
usual-care control group among non-metastatic colon cancer survivors. 
Primary Research Questions & Hypotheses 
The primary research questions and hypotheses addressed by the COURAGE trial in this 
dissertation were as follows: 
Specific Aim 1: To quantity and describe the dose-response effects of 
moderate-intensity aerobic exercise on VAT, measured with a novel and 
validated method using dual energy x-ray absorptiometry. 
Hypothesis: We hypothesized that exercise will favorably reduce VAT in dose-
response fashion. 
Specific Aim 2:  To quantify and describe the dose-response effects of 
moderate-intensity aerobic exercise on levels of fasting insulin. 
 16 
Hypothesis: We hypothesized that exercise will favorably reduce levels of 
fasting insulin in dose-response fashion. 
Specific Aim 3: To quantify and describe demographic, clinical, and 
geographical characteristics that associate with eligibility screening and study 
enrollment in the COURAGE trial. 
Hypothesis: We hypothesized that demographic, clinical, and geographical 
characteristics will be associated with eligibility screening and study enrollment. 
 
Placing the Courage Trial into Larger and Longer-Term Context  
Exercise has potential pharmacologic properties that are similar to many drugs [Vina et 
al, 2012].  Exercise and drug interventions are similar in terms of their mortality benefits 
in the secondary prevention of coronary heart disease, rehabilitation after stroke, 
treatment of heart failure, and the prevention of diabetes [Naci and Ioannidis, 2013].  
The developmental pipeline for bringing exercise to the standard of clinical care for 
adjuvant colon cancer should progress through a similar pipeline to that of drug 
development.  Because exercise is a complex and multifaceted behavior, the level of 
preliminary evidence required to undertake a definitive phase III randomized controlled 
trial should be abundant and consistently demonstrate the safety, feasibility, and 
physiologic alterations that support the hypothesis of a causal relationship.  We have 
proposed a sequential phased process that systematically evaluates the critical 
questions that should be answered prior to undertaking a phase III trial in this area 
(Figure 1.6).  At each sequential phase the physiologic specificity of the potential 
benefits of exercise on disease outcomes is deepened.  First, as with a drug, the 
feasibility and safety of various exercise doses must be established.  Second, we aim to 
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understand how biomarkers representing various physiologic pathways respond to an 
exercise stimulus.  Such biomarkers may include VAT (adiposity), insulin (metabolic), C-
reactive protein (inflammation), or soluble intercellular adhesion molecules (endothelial 
axis).  The COURAGE trial will address these two phases. Subsequent to the COURAGE 
trial, it will be necessary to examine how specific pathways (i.e., PI3K-Akt-mTOR) 
change in response to exercise and how this may affect metastatic potential.  Assuming 
these hypotheses are supported, smaller multisite trials can be undertaken to 
demonstrate the ability to coordinate and concentrate research efforts.  After a 
successful multi-site feasibility study, a definitive phase III trial with a clinical endpoint 
can be initiated.  This process is likely to be iterative as new questions and unanticipated 
logistical, methodological, and scientific barriers arise.  This proposed human 
developmental pipeline should be supplemented with ongoing preclinical studies.  This 
proposed human developmental pipeline will systematically generate high quality data 
that will help to inform the standard of clinical care for adjuvant colon cancer. 
Summary  
The propensity to recur is a formidable reality for colon cancer survivors and presents a 
critical barrier to promote long term survivorship.  Excess VAT and hyperinsulinemia are 
hypothesized as important host factors that may promote colon cancer recurrence and 
metastasis.  Exercise has emerged as an adjuvant intervention that may confer 
recurrence and survival benefits for people with colon cancer.  However, the underlying 
biologic or biobehavioral pathways that mediate the relationship between exercise and 
colon cancer outcomes remain unidentified.  It is plausible that exercise reduces VAT 
and/or insulin levels, thereby reducing the pro-tumorigenic milieu, and minimizing the 
growth and progression of residual local and distant micro-metastases.  The preliminary 
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data supporting these associations are strong, consistent with biologic plausibility, occur 
in dose-response fashion, and have select aspects that are supported with randomized 
data.  Interventions to decrease VAT and/or fasting insulin among colon cancer survivors 
will help to clarify how exercise may alter pathways that are hypothesized to influence 
disease outcomes and the sensitivity of such pathways to respond to different doses of 
exercise.  Such data will improve the specificity of exercise prescriptions provided to 
colon cancer survivors and strengthen the hypothesis of a causal relationship between 
exercise and disease outcomes.  In addition, the data from this dissertation will help to 
refine key trial design characteristics for future randomized controlled trials in this area. 
The long-term goal of this line of research is to generate definitive answers to the 
questions “Should I exercise?  Should I lose weight?  What will improve my chances?” 
that are asked by the 83,000 men and women who will be told “you have colon cancer” 
each year.  Seven in ten colon cancer survivors cite fear of disease recurrence as their 
principal health concern [Baker et al, 2005].  Thoughts about recurrence are intrusive, 
physically and psychologically debilitating, and alter long-term family and financial 
planning [Simard et al, 2013].  These patients deserve to know how the choices they 
make to purposefully alter lifestyle behaviors may influence their disease outcomes.  
This information will empower patients, families, and providers with practical solutions to 
improve outcomes. 
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Figure 1.1 Mechanistic pathway describing how visceral adipose tissue promotes a pro-
tumorigenic environment.  Adapted from [Doyle et al, 2012]. 
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Figure 1.2 Illustration of differences in body mass index (BMI) and visceral adipose 
tissue among colorectal cancer patients using computed tomography at the level of the 
umbilicus. 
 
Red shading indicates visceral adipose tissue area (VFA).  Blue shading indicates 
subcutaneous tissue area (SFA).  Patient ‘a’ has a BMI of 24.0 kg/m2 with a VFA/SFA of 
1.49.  Patient ‘b’ has a BMI of 48.0 kg/m2 and a VFA/SFA ratio of 0.35.  Adapted from 
[Ballian et al, 2012]. 
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Figure 1.3 Smoothing spline plot of disease-free survival and hours per week of walking. 
 
Thick solid line represents that hazard ratio and dashed lines represent the 95% 
confidence intervals.  Adapted from [Meyerhardt et al, 2006]. 
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Figure 1.4 Relationship between amount of exercise per week and percent visceral fat 
change.  Adapted from [Slentz et al, 2009]. 
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Figure 1.5 The trial enrollment process: “who are these patients and how did they get 
here?”  Adapted from [Gross et al, 2002]. 
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Figure 1.6 Sequential phases of developing randomized controlled trials to examine the 
relationship between exercise and disease outcomes in colon cancer.  Adapted from 
[Campbell et al, 2000]. 
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Abstract 
Background: Observational studies indicate that higher volumes of physical activity are 
associated with improved disease outcomes among colon cancer survivors.  The aim of 
this report is to describe the purpose, study design, methods, and recruitment results of 
the COURAGE trial, a National Cancer Institute (NCI) sponsored, phase II, randomized, 
dose-response exercise trial among colon cancer survivors. 
Methods/Results: The primary objective of the COURAGE trial is to quantify the 
feasibility, safety, and physiologic effects of low-dose (150 min·wk-1) and high-dose (300 
min·wk-1) moderate-intensity aerobic exercise compared to usual-care control group over 
six months.  The exercise groups are provided with in-home treadmills and heart rate 
monitors.  Between January and July 2015, 1,433 letters were mailed using a 
population-based state cancer registry; 126 colon cancer survivors inquired about 
participation, and 39 were randomized onto the study protocol.  Age was associated with 
inquiry about study participation (P<0.001) and randomization onto the study protocol 
(P<0.001).  No other demographic, clinical, or geographic characteristics were 
associated with study inquiry or randomization.  The final trial participant was 
randomized in August 2015.  Six month endpoint data collection was completed in 
February 2016. 
Discussion:  The recruitment of colon cancer survivors into an exercise trial is feasible.  
The findings from this trial will inform key design aspects for future phase 2 and phase 3 
randomized controlled trials to examine the efficacy of exercise to improve clinical 
outcomes among colon cancer survivors. 
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Introduction  
There are 103,000 people diagnosed annually with colon cancer in the United States 
[Siegel et al, 2014].  Among those diagnosed, 39% will have localized colon cancer 
(confined to the primary site; stage I-II), 36% will have regional colon cancer (spread to 
regional lymph nodes; stage III), and 20% will have metastatic disease (spread to distant 
organs; stage IV) [DeSantis et al, 2014, Siegel et al, 2014].  Among those without 
metastatic disease, five year survival rates for localized and regional colon cancer are 
90% and 70%, respectively [Siegel et al, 2014].  Surgery is the primary treatment 
modality for localized and regional colon cancer, with curative resection occurring in 80-
85% of patients [Clinical Outcomes of Surgical Therapy Study Group, 2004, Lacy et al, 
2002].  Those with regional disease may also receive adjuvant chemotherapy to reduce 
the risk of recurrent disease [Meyerhardt and Mayer, 2005].  Despite the efficacy of 
surgical resection and adjuvant chemotherapy, 20-50% of patients with localized and 
regional colon cancer develop recurrent disease [André et al, 2004, Quasar 
Collaborative Group, 2007].  Eighty percent of recurrences occur within the first three 
years after treatment, and 91% of patients who develop a recurrence by three years, die 
before five years [Sargent et al, 2005].  Consequently, there exists a need to identify 
additional adjuvant therapies that can be prescribed at the conclusion of standard colon 
cancer therapy (e.g., surgery and chemotherapy) to minimize the risk of recurrence.  
Such adjuvant therapies may include the modification of lifestyle behaviors. 
Physical activity or exercise is a modifiable lifestyle behavior that is associated with 
disease outcomes among colon cancer survivors.  Among 832 stage III colon cancer 
survivors, participation in approximately 300 min·wk-1 (18 to 27 MET-hours) of physical 
activity after diagnosis was associated with a 45-49% improvement in disease-free 
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survival (defined as cancer recurrence or death from any cause), and a 29-63% 
improvement in overall mortality [Meyerhardt et al, 2006].  This observation has been 
replicated in multiple cohorts of men [Campbell et al, 2013, Meyerhardt et al, 2009] and 
women [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006], and is 
independent of known demographic, clinico-pathologic, and treatment-related prognostic 
factors [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006, Meyerhardt et 
al, 2006, Meyerhardt et al, 2009].  A consistent finding in all of these cohort studies is 
that post-diagnosis physical activity is associated with disease outcomes in a dose-
response fashion, such that larger doses of physical activity or exercise, up to 
approximately 300 minutes per week (min·wk-1), is associated with more favorable 
disease outcomes [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006, 
Meyerhardt et al, 2006, Meyerhardt et al, 2009].  This dose-response pattern has been 
confirmed in several meta-analyses [Des Guetz et al, 2013, Je et al, 2013, Schmid and 
Leitzmann, 2014].  However, it is unknown if doses of exercise as large as 300 min·wk-1 
are behaviorally feasible and have tolerable safety profiles for colon cancer survivors 
when compared to smaller doses of exercise, such as 150 min·wk-1 as is currently 
recommended by the American Cancer Society [Rock et al, 2012], American College of 
Sports Medicine [Schmitz et al, 2010], and the National Comprehensive Cancer Network 
[National Comprehensive Cancer network, 2013].  Furthermore, the biological or 
biobehavioral pathways through which exercise may impact disease outcomes among 
colon cancer survivors are unknown.  Evaluating potential biomarkers and/or mediators 
involved in the anti-cancer effects of exercise and the sensitivity of such biomarkers 
and/or mediators to respond to different doses of exercise will help to identify the optimal 
dose of exercise to improve outcomes and guide clinical decisions and 
recommendations. 
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Aims of this Report  
The aims of this report are two-fold.  First, we describe the purpose, study design, and 
methods of the COURAGE trial, a National Cancer Institute (NCI) sponsored, phase II, 
randomized, dose-response exercise trial of two distinct doses of moderate-intensity 
aerobic exercise compared to a usual-care control group among colon cancer survivors.  
Second, we present recruitment results to describe what demographic, clinical, or 
geographic characteristics are associated with inquiry about study participation and 
randomization onto the study protocol.  Identifying the characteristics associated with 
inquiry about study participation and randomization onto the study protocol will provide 
empirical evidence to describe trial generalizability to the broader population of colon 
cancer survivors. 
Study Objectives & Outcomes 
The primary objective of the COURAGE trial is to quantify the feasibility, safety, and 
physiologic effects of low-dose (150 min·wk-1) aerobic exercise, high-dose (300 min·wk-1) 
aerobic exercise, or usual-care control, among non-metastatic colon cancer survivors 
over six months (Figure 2.1).  The primary outcomes include exercise adherence, 
adverse events, soluble intercellular adhesion molecule-1 (sICAM-1) and soluble 
vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.  Key secondary 
outcomes include visceral adipose tissue (VAT), and fasting insulin.  Exploratory 
outcomes include the enumeration of circulating tumor cells (CTCs), functional status, 
and patient-reported outcomes and quality of life measures. 
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Methods  
All study activities as described below were reviewed and approved by the University of 
Pennsylvania Human Subjects Protection Programs.  The trial was registered with 
ClinicalTrials.gov as NCT02250053. 
Eligibility Criteria 
To balance the goals of recruiting a homogeneous study cohort with recruitment 
feasibility we a priori implemented a phased recruitment strategy which systematically 
broadened eligibility criteria in each successive phase of recruitment.  In phase 1 (most 
strict) the inclusion criteria were as follows: histologically-confirmed stage II-III colon 
cancer; completed surgical resection and adjuvant chemotherapy ≤24 months before 
entering the study; ≤120 min·wk-1 of self-reported moderate or vigorous intensity physical 
activity using the Paffenbarger Physical Activity Questionnaire [Paffenbarger et al, 1993]; 
age ≥18 years; written physician approval; no additional surgery planned within the six 
month intervention (including colostomy reversal); and the ability to walk unaided for six 
minutes.  In phase 2 (less restrictive) the inclusion criteria were broadened to increase 
the baseline self-reported physical activity level from ≤120 min·wk-1 to <150 min·wk-1, 
and expanded the time since completing surgical resection and adjuvant chemotherapy 
from ≤24 months to ≤36 months.  In phase 3 (least restrictive) the inclusion criteria were 
broadened from histologically-confirmed stage II-III colon cancer to histologically-
confirmed stage I-III colon cancer, and expanded the time since completing surgical 
resection and adjuvant chemotherapy to any period. 
During all phases of recruitment, the exclusion criteria were as follows: history of another 
primary cancer (other than non-melanoma skin-cancer); evidence of metastatic colon 
cancer; planning to receive any additional adjuvant chemotherapy or surgery (i.e., 
 31 
ostomy reversal); pregnant or breast feeding; unable to provide baseline blood sample; 
cardiac conditions, including the following: myocardial infarction or coronary 
revascularization procedure within the past three months, uncontrolled hypertension, 
defined as a systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥100 mm 
Hg, high-risk or uncontrolled heart arrhythmias, clinically significant heart valve disease, 
decompensated heart failure, or known aortic aneurysm; and any other condition which, 
in the opinion of the investigator, may impede testing of the study hypothesis or make it 
unsafe to engage in the exercise program. 
Participant Recruitment  
Potentially-eligible study participants were recruited through the Pennsylvania Cancer 
Registry (PCR) [Pennsylvania Department of Health].  The PCR is a member of the 
North American Association of Central Cancer Registries (NAACCR) that is responsible 
for collecting information on all new cases of cancer diagnosed and/or treated in the 
state of Pennsylvania (i.e., the PCR is population-based).  The PCR has received Gold 
Certification from the NAACCR for excellence in areas of completeness, quality, and 
timeliness of cancer incidence reporting.  Potentially-eligible study participants were 
listed in the PCR with international classification of diseases for oncology third edition 
(ICD-O-3) codes for colon cancer (C18.0, C18.2-C18.9).  Cancer of the rectum (C20.9) 
was not eligible for participation.  To minimize anticipated concerns regarding travel 
burden into the city of Philadelphia from surrounding suburbs, potentially-eligible 
participants were recruited from Philadelphia County and four surrounding counties 
(Bucks, Montgomery, Chester, and Delaware).  Using an envelope with the University of 
Pennsylvania School of Medicine logo, potentially-eligible participants were sent one 
letter via postal mail that included an invitation to participate signed by the principal 
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investigator, a one page flyer describing the study, the name and contact information 
(email, telephone) of the study coordinator, and a brochure describing the PCR.  The 
one page flyer that described the study included statements that mentioned the provision 
of an in-home treadmill and an individualized exercise program.  Mailings were 
completed in four successive waves as new incident data became available from the 
PCR (January, March, May, and July).  This recruitment approach has been used by our 
research group in prior studies among breast cancer survivors [Rogerino et al, 2009]. 
Participant Screening  
Screening was conducted via a telephone interview.  The telephone interview included a 
brief description of the study, systematically queried callers about each of the above-
described inclusion and exclusion criteria, and administered the physical activity 
readiness questionnaire (PAR-Q) [Shephard, 1994].  The PAR-Q is a seven item 
questionnaire that identifies signs of cardiovascular disease, orthopedic conditions, and 
medications that could affect physiologic responses to an increase in physical activity. 
The PAR-Q has excellent sensitivity (close to 100%) and specificity (80%) for detecting 
medical contraindications to exercise [Shephard, 1994].  After screening, eligible 
participants were invited to the University of Pennsylvania to meet with the study 
coordinator for 30-45 minutes to discuss the goals, objectives, risks, and benefits of the 
study in detail.  At that time, written informed consent was obtained from eligible 
participants wishing to enroll in the study. 
Study Measures 
After obtaining written informed consent, the study coordinator sent a physician approval 
form to each of the participant’s physicians, which often included the primary care 
physician, surgical and/or medical oncologist, and other appropriate internal medicine 
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specialists (e.g., cardiologist for participants with pre-existing cardiac conditions).  The 
physician approval form included a brief description of the study, the results of the PAR-
Q screening questionnaire, and a request that the physician review this information and 
provide approval that they believe their patient is medically fit to participate in a 
moderate-intensity aerobic exercise study.  After obtaining written physician approval, 
the study participant completed a clinic visit at the University of Pennsylvania Center for 
Clinical and Translational Research Center.  The specific measures of the clinic visit are 
described in detail below.  All measures described below are completed at baseline and 
at six months (except clinical characteristics 4.4.1).  All measures are conducted by staff 
blinded to study group. 
Clinical Characteristics 
Tumor-related characteristics including date of diagnosis and treatment completion, 
stage (American Joint Committee on Cancer, 7th edition [Edge et al, 2010]), primary 
tumor location within the colon, depth of tumor invasion (T-stage), number of positive 
resected lymph nodes (N-stage), grade of histologic differentiation, presence of 
lymphovascular invasion, and adjuvant chemotherapy are abstracted from the PCR 
database, medical record review, and from treatment summary reports obtained from the 
providing physician.  Comorbidities and current medication and supplement use are 
obtained using the Chronic Disease Scale [Von Korff et al, 1992].  The above-described 
variables that were extracted from the PCR database were utilized to examine how 
demographic, clinical, or geographic characteristics were associated with inquiry about 
study participation and randomization onto the study protocol. 
Blood Sample 
 34 
A total of 50mL of blood is collected by a licensed phlebotomist.  Blood is collected after 
a minimum of six hours of fasting, which is verified prior to venipuncture.  Blood samples 
are processed using standardized laboratory procedures and aliquots of serum and 
EDTA-preserved plasma are stored in -80°C freezers.  In addition to the biomarker 
assays described below, additional aliquot samples are stored for future exploratory 
analyses. 
sICAM-1 is analyzed using an R&D systems enzyme linked immunoabsorbent assay 
[Adamopoulos et al, 2001, Craft et al, 2008].  The inter-assay coefficient of variation and 
sensitivity are 5.4%, and 0.049-0.254 ng/mL, respectively.  sVCAM-1 is analyzed using 
an R&D systems enzyme linked immunoabsorbent assay [Adamopoulos et al, 2001, 
Craft et al, 2008].  The inter-assay coefficient of variation and sensitivity are 7.7%, and 
0.17-1.26ng/mL, respectively.  Fasting insulin is analyzed with a radioimmunoassay 
(Millipore).  The inter-assay coefficient of variation is 6%, and sensitivity ranges from 2.0-
200.0 μU/mL.  Fasting glucose is analyzed with immuno-nephelometry assay.  The inter-
assay coefficient of variation is 2%, and sensitivity ranges from 0.6-45.0mmol/L.  The 
measurement of glucose serves as a quality control to enable the attribution of elevated 
fasting levels to insulin resistance, rather than latent type 2 diabetes or blood samples 
that were collected in a non-fasting manner.  The homeostatic model (HOMA) is 
calculated to quantify insulin resistance [Wallace et al, 2004].  Other associated 
metabolic biomarkers including glycated hemoglobin (HbA1c), insulin-like growth factor-
1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP3), and C-peptide are also 
analyzed. 
CTCs from venous blood are isolated using geometrically enhanced differential 
immunocapture (GEDI) [Gleghorn et al, 2010].  GEDI is a microfluidic platform that 
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utilizes antibody coated obstacles to capture rare cells within anticoagulated whole 
blood.  To capture CTCs, obstacles are coated with an antibody specific to epithelial cell-
adhesion molecule (EpCAM), an epithelial cell-specific marker.  After washes, captured 
cells are stained with the nuclear marker DAPI and fluorescently labeled antibodies to 
the leukocyte marker CD45 and the epithelial cell marker Pdx-1.  Using fluorescence 
microscopy, Pdx1+/DAPI+/CD45- EpCAM captured cells with intact cellular morphology 
are counted as CTC’s by a blinded technician. 
Anthropometric Measures 
For all anthropometric measures participants wear study-provided medical scrubs (top 
and trousers).  Height is measured using a wall-mounted digital stadiometer without 
shoes to the nearest 0.1 centimeter.  Weight is measured using a calibrated digital scale 
to the nearest 0.1 kilogram.  Height and weight are used to calculate body mass index 
(kg/m2).  Waist and hip circumference are measured using a Gulick spring-loaded tape 
measure to the nearest 0.1 centimeter.  Sagittal abdominal diameter is measured using 
an abdominal caliper (Holtain-Kahn) to the nearest 0.1 centimeter [Zamboni et al, 1998].  
Body composition is measured using whole-body dual-energy x-ray absorptiometry 
(DXA; Hologic Discovery; APEX v 13.4 software).  DEXA is used to quantify VAT (cm2), 
subcutaneous adipose tissue (cm2), total fat mass (kg), and lean mass (kg).  DXA-
derived VAT correlates with computed tomography derived VAT (r=0.93; P<0.001) 
[Micklesfield et al, 2012], and is reliable across a large weight spectrum [Bredella et al, 
2013]. 
Cardiopulmonary & Functional Status 
A resting electrocardiogram is completed to identify any clinically-significant cardiac 
conduction abnormalities [i.e., 3rd degree heart block, uncontrolled arrhythmia, or ST-
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segment depressions (>3 mm)] that may preclude participation in exercise.  Functional 
status is measured using the six minute walk test (6MWT), following the guidelines of 
American Thoracic Society [ATS Committee on Proficiency Standards for Clinical 
Pulmonary Function Laboratories, 2002].  The outcome of the 6MWT is the distance 
walked in six minutes, recorded to the nearest meter.  The 6MWT is reliable, and 
correlated with physiologic impairments of strength and power of the lower extremities 
[Guyatt et al, 1985].  The 6MWT is also used to identify persons who may develop signs 
and symptoms of cardiac distress, such as chest pain or severe shortness of breath 
during exertion, which may preclude participation in exercise.  
Physical Activity 
Physical activity is measured using both self-reported and objective measures.  The 
Paffenbarger Physical Activity Questionnaire queries activities including flights of stairs 
climbed, blocks walked, and other leisure-time physical activities performed on a typical 
day or week [Paffenbarger et al, 1993].  The outcome of the Paffenbarger Physical 
Activity Questionnaire is the total energy expenditure associated with leisure-time 
physical activity, quantified in multiples of resting energy expenditures (METs) using the 
compendium of physical activities [Ainsworth et al, 2000].  The ActiGraph model GT3X+ 
accelerometer is worn for seven consecutive days.  Participants are provided with a 
diary to document accelerometer wear time.  The ActiGraph is a valid and reliable 
objective measure of ambulatory activity [Bassett et al, 2000].  The main outcomes 
obtained from the ActiGraph accelerometer will be the number of minutes of moderate-
to-vigorous physical activity (≥3 METs) and activity-related energy expenditure (kcals), 
calculated using validated cut-points appropriate for adults [Troiano et al, 2008]. 
Dietary Intake 
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Dietary intake is measured using three day dietary records collected during two 
weekdays and one weekend day [Luhrmann et al, 1999].  Food records are entered into 
the Nutrition Data System for Research software (2009 version) by registered dietitians.  
The resulting data includes 165 micro- and macronutrient variables.  Daily caloric intake 
is the primary covariate of interest to determine if any observed physiologic changes are 
due to exercise or the result of concurrent dietary alterations. 
Patient-Reported Outcomes & Quality of Life Measures 
In addition to the above-described physiologic measures, participants complete 
questionnaires relating to demographics, alcohol and smoking habits, and various self-
report questionnaires that are known to influence the quality of life of colon cancer 
survivors [Committee on Cancer Survivorship: Institute of Medicine and national 
Research Board, 2006, Harrington et al, 2010].  Overall quality of life is assessed using 
the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) [Ward et al, 1999], 
and the SF-36 [Ware and Sherbourne, 1992].  Pain is assessed using the Brief Pain 
Index [Cleeland and Ryan, 1994].  Sleep quality is assessed using the Pittsburgh Sleep 
Quality Index [Buysse et al, 1989].  Bowel function is assessed using the Assessment of 
Bowel Function Questionnaire [Haddock et al, 2007].  Cancer-related fatigue is 
assessed using the Brief Fatigue Inventory [Mendoza et al, 1999].  Concerns about 
cancer recurrence are measured with the Fear of Cancer Recurrence Inventory [Simard 
and Savard, 2009]. 
Safety & Adverse Events 
Participants in all study groups are asked each week by the study coordinator to identify 
any incident health events.  All reported health events are graded in accordance with the 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [US Department 
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of Health and Human Services, 2009].  At the end of the study, all participants complete 
a healthcare utilization and musculoskeletal injury questionnaire asking about any 
healthcare encounters and injuries experienced while in the study that may have not 
been previously reported [Brown et al, 2012a, Warren and Schmitz, 2009].  The data 
safety monitoring plan for this study focuses on monitoring by the principal investigator, 
along with prompt reporting of excessive adverse events and any serious adverse 
events to the National Institutes of Health and the Institutional Review Board at the 
University of Pennsylvania. 
Randomization  
After completion of baseline measurements, participants were stratified by stage of colon 
cancer (I vs. II vs. III) and randomized in a 1:1:1 ratio to either the low-dose (150 min·wk-
1) aerobic exercise group, the high-dose (300 min·wk-1) aerobic exercise group, or the 
usual-care control group. 
Treatment Plan  
Participants randomized into the low-dose and high-dose exercise groups increase their 
exercise to 150 min·wk-1 and 300 min·wk-1, respectively.  Participants randomized into 
the low-dose and high-dose exercise groups are provided with an in-home treadmill 
(LifeSpan Fitness, TR1200i, Salt Lake City, UT).  Treadmills are ordered for participants 
on the day of randomization.  Participants who were unable to accommodate a treadmill 
in their home were provided with a one-year health club membership (or other 
membership of similar monetary value) to a facility of the participants choosing.  After 
treadmill delivery and setup, participants meet with a certified clinical exercise 
physiologist at the University of Pennsylvania to introduce the exercise prescription, and 
familiarize the participant to use of the treadmill, the completion of exercise logs, use of 
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a heart rate monitor (described below), appropriate warm-up and cool-down, stretches, 
and proper footwear for aerobic exercise.  The exercise physiologist provides ongoing 
behavioral support and monitoring of exercise adherence to the study protocol 
throughout the duration of the study.  Behavioral support is individualized to each 
participant to include the benefits of exercise for colon cancer survivors, strategies to 
integrate exercise into day-to-day activities, how to identify and overcome barriers to 
exercise, recruiting friends and family members to provide support in reaching their 
exercise goals, and how to set simple, measureable, attainable, realistic, and timely 
(SMART) goals [Weinberg, 1994] to promote exercise self-efficacy and compliance 
[Courneya et al, 2008].  The modes through which behavioral support is delivered are 
tailored to participant preference to maximize effectiveness of communication and 
include in-person sessions (as described below), complemented with weekly 
telephone/text, or email contact.  If participants have upcoming scheduled medical 
procedures that may result in missed exercise (i.e., the day of a surveillance 
colonoscopy) the participant works with the exercise physiologist to develop a plan for 
maintaining optimal exercise adherence.  If injury or illness prevents exercise for ≥1 
week, minutes are allowed to be made-up upon return to exercise. 
Exercise compliance is monitored through the use of self-reported and objective 
measures.  All participants randomized to the low-dose and high-dose exercise groups 
are provided with an exercise log to record the date, modality of aerobic exercise used 
(any form of aerobic exercise will be acceptable, though most participants elect to use 
the study provided in-home treadmill), treadmill speed and incline, average heart rate 
obtained from a study-provided heart rate monitor, duration of exercise, completion of 
appropriate warm up and cool down, and any new or worsening musculoskeletal 
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symptoms.  Participants are provided with a Polar Heart Rate Monitor (Polar Electro Inc., 
RS400, Lake Success, NY).  The heart rate monitors record up to 99 sessions of 
exercise.  Heart rate monitor data is downloaded to a computer to enable objective 
monitoring of exercise adherence.  Participant exercise logs and objective heart rate 
data are discussed and reviewed by the exercise physiologist to provide feedback 
including encouragement, problem solving, and long-term planning to the study 
participant. 
For both the low-dose and high-dose exercise groups, the initial exercise dose 
prescribed in week one of the study is 60 min.  This relatively low volume of exercise 
allows participants to gain confidence in exercising, allows for time to determine how 
exercise will be integrated into their schedule, and allows the participant to work towards 
a practical initial exercise goal that is not overwhelming.  Exercise is titrated by 30 
min·wk-1 as the participant successfully responds to the exercise dose prescribed in the 
prior week.  During the exercise titration phase, participants meet with the exercise 
physiologist at the university research center each week to review the exercise 
completed in the prior week, discuss any new musculoskeletal symptoms, side effects, 
or barriers to exercise.  At that time exercise is then titrated for the following week.  The 
planned exercise volume of the low-dose and high-dose exercise groups are 150 
min·wk-1 and 300 min·wk-1, respectively.  In the absence of dose-limiting toxicity, low-
dose and high-dose study participants have their exercise volume fully titrated by week 4 
and 9 of the study, respectively.  Delivered over six months, the planned total dose of 
exercise delivered to the low-dose and high-dose exercise groups is 3,720 minutes and 
6,740 minutes, respectively.  The intensity of all exercise is prescribed between 50 and 
70% of the age-predicted maximum heart rate, consistent with that of moderate-intensity 
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aerobic exercise (3-6 METs) [Ainsworth et al, 2000].  Participants are allowed to 
complete exercise sessions that are ≥10 minutes to ≤75 minutes in length toward the 
goal of increasing behavioral feasibility of completing the planned exercise dose. 
Exercise adherence is quantified using objective heart rate monitoring.  However, heart 
rate monitors may fail due to technical error or exceed the available memory capacity.  
In our prior dose-response exercise trial this situation occurred <5% for all exercise 
sessions [Schmitz et al, 2015a, Schmitz et al, 2015b].  In this scenario, objective 
monitoring is used to validate at least three weeks of self-report logs.  Upon validation, 
self-report logs are accepted as a valid substitute for objective heart rate data until heart 
rate monitor function has been restored.  Exercise adherence outcomes include the 
number of minutes of exercise completed within the target heart rate range for each 
week of the study and over six months, and the percent of prescribed minutes completed 
in each week of the study and over six months. 
Participants randomized into the usual-care control group are asked to maintain their 
pre-study levels of physical activity and/or follow the recommendations provided by their 
physician.  After completing six month measures, control group participants are provided 
with an in-home treadmill and individualized exercise program, similar to that prescribed 
to the two exercise groups.  Upon study completion, all participants are allowed to keep 
their study-provided treadmills. 
Statistical Considerations  
Thirty nine participants were randomized to the three study arms (control, 150 min·wk-1, 
300 min·wk-1), toward the goal of having 30 participants (10 per arm) with study endpoint 
data (76% completion rate).  This sample size provides adequate statistical power for 
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the primary outcome biomarkers (sICAM-1 and sVICAM-1) with a hypothesis for a linear 
dose-response trend.  Against the hypothesis of a dose-response relationship with 
decreases of 22 and 44 units for low-dose and high-dose respectively for sICAM-1 and 
74 and 148 units for sVCAM-1, 30 participants provide 80% power for two tests (one for 
sICAM-1 and one for sVCAM-1), each tested with a type I error rate of 0.025, to maintain 
the experiment-wise overall error rate of 0.05.  The estimated change in sICAM-1 and 
sVCAM-1 is clinically meaningful and consistent with prior exercise interventions in non-
cancer populations [Adamopoulos et al, 2001, Hamdy et al, 2003, Leinonen et al, 2003, 
Saetre et al, 2011, Tonjes et al, 2007].  
The target sample size provides sufficient statistical power to examine key secondary 
outcomes that include VAT and fasting insulin.  Against the hypothesis of a dose-
response relationship with an increase in VAT of +8.6% (+14 cm2) in the control group, 
+1.7% (+2.9 cm2) in the low-dose group, and -6.9% (-11.6 cm2) in the high-dose group 
and a pooled standard deviation of ±17%, 30 participants provide 80% power tested with 
a type I error rate of 0.05.  These changes are estimated from a prior dose-response 
exercise study [Slentz et al, 2005, Slentz et al, 2009, Slentz et al, 2004].  Against the 
hypothesis of a dose-response relationship with an increase in fasting insulin of +1.1 
μU/mL in the control group, –0.5 μU/mL in the low-dose group, and –0.9 μU/mL in the 
high-dose group, and a pooled standard deviation of ±0.7 μU/mL, 30 participants provide 
80% power tested with a type I error rate of 0.05.  These changes are estimated from a 
prior dose-response exercise study [Houmard et al, 2004].  The exploratory outcomes 
for this trial include enumeration of CTCs, functional status, and patient-reported 
outcomes and quality of life measures.  There are limited data to determine what 
proportion of colon cancer survivors who have completed adjuvant therapy for colon 
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cancer will have enumerable CTCs.  Further, it is unknown how exercise may impact 
CTC volume.  Consequently, this outcome is considered exploratory with no directional 
hypothesis.  We hypothesize that functional status, and patient-reported outcomes and 
quality of life measures will improve in dose-response fashion. 
To identify characteristics associated with inquiry about study participation and 
randomization onto the study protocol we had 80% power to detect an odds ratio as 
small as 1.3 and 1.7, respectively.  Both sets of analyses were tested with the type I 
error rate of 0.05. 
 
Statistical Analysis  
The feasibility of exercise is quantified by comparing the proportion of participants in 
each group who achieve ≥80% of their prescribed exercise dose.  The safety of exercise 
is quantified by comparing the proportion of participants who experience adverse events 
in each of the three study groups.  For each of the primary and secondary physiologic 
outcomes, a linear mixed-effects regression model is used to compare the change in 
biomarker levels for each group while adjusting for the baseline value of the dependent 
variable.  All analyses follow an intention-to-treat approach.  Models are fit to include 
dose as a linear term, and model fit is examined using standard methods.  Alternatives 
to a linear dose trend include transformations of dose, such as average actual dose, log-
transformed dose per week, or second-order polynomial (i.e., dose and dose2).  In the 
absence of a dose-response relationship, each of the two intervention groups (low-dose 
and high-dose exercise) is compared to the control arm using a two-sided t-test. 
Characteristics associated with inquiry about study participation and randomization onto 
the study protocol are identified using two sets of logistic regression analyses: one set to 
compare characteristics between those who inquired about study participation versus 
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those who do not inquire about participation; and one set to compare characteristics 
between those who were randomized onto the study protocol versus those who were not 
randomized onto the study protocol.  Characteristics with P<0.20 in univariable models 
are entered simultaneously in a multivariable model. 
Results  
Between January and July 2015, 1,435 letters were delivered to potentially-eligible 
persons with an ICD-O-3 code for colon cancer (Table 2.1).  Two recipients of the study 
letter expressed concern about disclosure of private health information (0.001%).  These 
two recipients clarified their concerns with the principal investigator and were provided 
with the appropriate contact at the PCR.  These two participants were excluded from the 
analyses presented herein reducing the analytic sample to 1,433.  Colon cancer 
survivors who were invited to participate in this trial were representative of colon cancer 
survivors in the United States with respect to age, sex, race, and disease stage [Siegel 
et al, 2014].  The median distance from the University of Pennsylvania to the zip-code 
centroid of survivors invited to participate was 20 kilometers [interquartile 25-75% range: 
10-33] and ranged from 0.4 (~4 city blocks) to 71 kilometers. 
Among the 1,433 colon cancer survivors invited to participate, 126 (8.8%) inquired about 
participation (Figure 2.2).  Eleven letters were mailed to screen one potentially-eligible 
participant.  In univariate analysis, colon cancer survivors who inquired about 
participation were younger [Odds Ratio: 0.82 per 5-year increment (95% CI: 0.76-0.88); 
P<0.001; Table 2.1], and were more likely to be treated with chemotherapy [Odds Ratio: 
1.68 (95% CI: 1.15-2.44); P=0.007], compared to those who did not inquire about 
participation.  In a multivariable model, age was associated with inquiring about study 
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participation [Odds Ratio: 0.83 per 5-year increment (95% CI: 0.77-0.89); P<0.001], but 
treatment with chemotherapy was no longer statistically significant [Odds Ratio: 1.43 
(95% CI: 0.98-2.10); P=0.066]. 
Among the 126 colon cancer survivors who inquired about participation, 102 were 
screened (81%).  The remaining 24 inquiries were not screened due to the study 
reaching its accrual goal.  Among the 102 colon cancer survivors screened, 46 (45%) 
were not interested in participating after learning more about the study.  The most 
commonly cited reasons for not being interested in the study were: being too busy 
(n=27; 59%); traveling into the city of Philadelphia would be too burdensome (n=13; 
28%); having other health concerns (n=5; 11%); and not wanting to be randomized to a 
group that may not include exercise (n=1; 2%).  Among the 102 colon cancer survivors 
screened, 17 (17%) were not eligible for participation after completing the telephone 
interview.  The most common reasons for ineligibility included: having a history of 
another cancer (n=8; 47%); currently exercising ≥150 min·wk-1 (n=3; 18%); having a 
cardiac condition (n=3; 18%); having recurrent or metastatic colon cancer (n=2; 12%); 
and being ≥36 months post cancer therapy (n=1; 5%). 
Among the 102 colon cancer survivors who were screened, 39 (38%) were randomized 
onto the study protocol.  Thirty seven letters were mailed to randomize one participant 
onto the study protocol.  Thirty-two participants were recruited during phase 1 eligibility 
(82%; most strict, January and March letter mailings), two participants in phase 2 (5%; 
less strict, May letter mailing), and five participants in phase 3 (13%; least strict, July 
letter mailing).  It is not clear why recruitment was most successful during the more 
restrictive phases of recruitment.  This may be due in part to the month in which 
participants were recruited which may have influenced their willingness to participate in a 
 46 
trial of lifestyle modification.  Compared with mailings in the month of January, mailings 
in the months of March, May, and July were associated with lower study inquiry and 
randomization rates, though these comparisons did not reach the threshold for statistical 
significance.  No participants had their physician decline approval to participate in the 
study.   In univariate analyses, colon cancer survivors who were randomized onto the 
study protocol were younger [Odds Ratio: 0.69 per 5-year increment (95% CI: 0.60-
0.78); P<0.001], and were more likely to be treated with chemotherapy [Odds Ratio: 2.66 
(95% CI: 1.32-5.39); P=0.006].  In a multivariable model, age was associated with 
randomization onto the study protocol [Odds Ratio: 0.70 per 5-year increment (95% CI: 
0.61-0.79); P<0.001], and treatment with chemotherapy was attenuated to marginal 
statistical significance [Odds Ratio: 2.01 (95% CI: 0.98-4.13); P=0.056].   
Among participants randomized to one of the two exercise groups, the median time from 
randomization to treadmill delivery and setup was 12 days [interquartile 25-75% range: 
10-15].  The final trial participant was randomized in August 2015.  Six month endpoint 
data collection was completed in February 2016. 
Discussion 
The COURAGE trial is an NCI sponsored, phase II, randomized, dose-response exercise 
trial that seeks to test the feasibility, safety, and physiologic effects of two distinct doses 
of moderate-intensity aerobic exercise compared to a usual-care control group among 
colon cancer survivors.  The results of this trial will provide preliminary information 
regarding the appropriate dose of aerobic exercise to optimize biomarkers that may 
mediate the relationship between exercise and colon cancer recurrence and clarify 
important design aspects for future phase 2 and phase 3 randomized controlled trials. 
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The primary recruitment method for the COURAGE trial was postal mailings to potentially-
eligible colon cancer survivors identified within the PCR.  Historically the recruitment of 
survivors of colon cancer into lifestyle modification trials has been challenging [Courneya 
et al, 2014, Ligibel et al, 2012, Meyerhardt, 2013, Pinto et al, 2013, van Waart et al, 
2015].  The reasons for this have not been fully explained, but may be due in part to the 
fact that colon cancer survivors are often older, have other comorbid health conditions, 
or residual toxicity from treatment (i.e., neuropathy), each of which may influence 
willingness to participate in a program of lifestyle modification [Brown and Schmitz, 
2014b].  Several studies have described their experience in recruiting colon cancer 
survivors into trials of lifestyle modification.  Pinto et al. recruited colon cancer survivors 
to a telephone-based physical activity intervention that aimed to increase participation in 
physical activity and improve self-reported quality-of-life outcomes [Pinto et al, 2013].  
Despite implementing various recruitment strategies (informational mailings, in-clinic 
recruitment, and community presentations), they were unable to recruit the required 
sample size of 134 participants; only randomizing 46 colon cancer survivors over 39 
months (~1.5 participants per month).  The CHALLENGE trial is a randomized phase 3 trial 
that seeks to recruit high-risk stage II and stage III colon cancer survivors to a three year 
physical activity program that aims to improve disease-free survival [Courneya et al, 
2008].  When the CHALLENGE trial was designed, recruitment of 962 colon cancer 
survivors was estimated to require 36 months (~27 participants per month).  Despite 
being open at 20 centers in Canada and 22 centers in Australia, over 55-months, 250 
colon cancer survivors have been randomized (~4.5 participants per month) [Courneya 
et al, 2014].  At a single institution over seven months, the COURAGE trial randomized 39 
colon cancer survivors (~5.5 participants per month).  At the time the trial met its planned 
accrual goal and closed to enrollment, an additional 24 potentially-eligible colon cancer 
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survivors expressed interest in participating and were waiting to be screened for trial 
enrollment. 
Each of the above-described trials is unique in their eligibility criteria, intervention 
characteristics, and endpoints of interest; our recruitment experience indicates that 
utilizing population-based cancer registries to recruit colon cancer survivors into a 
lifestyle modification trial is feasible.  The use of population-based cancer registries is 
disseminable to other cancer centers for accrual in multicenter trials, and may help to 
address an important barrier in the conduct of future lifestyle modification trials in this 
population.  A potential limitation to the use of population-based cancer registries is the 
six to nine month delay that may occur from the time of diagnosis to entry into the 
registry.  This limitation is of importance for trials that seek to modify behavior during or 
shortly after the completion of adjuvant therapy.  To address this limitation, many cancer 
registries now offer rapid case ascertainment which accelerates the reporting process to 
within one month of diagnosis [Beskow et al, 2006].  Another explanation to the high 
inquiry and screening rates in this study was the provision of an in-home treadmill.  The 
mailed flyer did describe this novel feature of the study.  As intended, this may have 
provided additional incentive to inquire about participation.  Given the potential benefit of 
exercise to improve disease outcomes, developing methods to recruit colon cancer 
survivors to participate in lifestyle modification trials is of critically high importance. 
Colon cancer survivors who inquired about trial participation were younger than those 
who did not inquire about trial participation.  Similarly, colon cancer survivors who were 
randomized onto the trial protocol were younger than those who were not randomized.  
This pattern is common to many trials, regardless of the intervention.  In an analysis of 
21 Southwest Oncology Group (SWOG) therapeutic trials that included 5,190 cancer 
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patients with 21 types of cancer, trial enrollees were significantly younger than non-
enrollees (P<0.001) [Unger et al, 2014].  These findings underscore the need for 
continued research to identify methods to communicate opportunities about clinical trial 
participation to older adults in an efficient and scalable manner.  In our multivariable 
model, treatment with chemotherapy was of marginal statistical significance for both 
inquiry about study participation (P=0.066) and randomization onto the study protocol 
(P=0.056).  This finding indicates the interest of patients with a higher probability of 
recurrence (i.e., high-risk stage II and stage III) to inquire and participate in a clinical trial 
of lifestyle modification.  Collectively, these data indicate that with exception of age, 
COURAGE trial participants are similar to the broader community of colon cancer survivors 
on measured characteristics, such as sex, race, time since diagnosis, clinico-pathologic 
tumor features, and geographic proximity to the University of Pennsylvania. 
In addition to obtaining important information about the feasibility and safety of the dose-
response effects of exercise among colon cancer survivors, this trial will gather 
preliminary data regarding physiologic changes in biomarkers that are hypothesized to 
mediate the relationship between exercise and disease outcomes.  sICAM-1 and 
sVCAM-1 are cell-adhesion molecules that promote the growth of existing micro-
metastases, and promote CTC differentiation, contact inhibition, and apoptosis [Paschos 
et al, 2009].  The down regulation of ICAM-1 attenuates the invasive potential of colon 
cancer cells and has been recommended as a therapeutic target [Howard et al, 2014].  
VCAM-1 has also been recommended as a therapeutic target [Schlesinger and Bendas, 
2015].  ICAM-1 and VCAM-1 have also been demonstrated to influence the metastatic 
potential of melanoma and gastric cancers [Giavazzi et al, 1992, Nakashio et al, 1997].  
We hypothesize that exercise may inhibit both seeding of distant organs and the 
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cultivation of the angiogenic milieu that is thought to be required for the growth of micro-
metastases.  We speculate that exercise may have direct effects on anti-cancer 
myokines, such as secreted protein acidic and rich in cysteine (SPARC) [Aoi et al, 2013], 
and may also have indirect effects through pathways that include improved metabolic 
homeostasis (i.e., VAT and insulin).  Several studies have demonstrated that abdominal 
adiposity, particularly VAT, is associated with poor colon cancer outcomes [Ballian et al, 
2012, Guiu et al, 2010, Haydon et al, 2006a, Moon et al, 2008, Prizment et al, 2010, 
Rickles et al, 2013].  VAT associates with insulin among colon cancer survivors (r=0.519; 
P<0.001) [Jiang et al, 2014], and is implicated in the recurrence of colon cancer 
[Giovannucci, 2001, Sandhu et al, 2002].  We hypothesize that exercise may reduce 
VAT and fasting insulin and potentially inhibit the growth of existing micro-metastases.  
As an exploratory aim, we will examine CTCs using the innovative GEDI platform 
[Gleghorn et al, 2010].  We hypothesize that CTCs disseminate via the circulation during 
the earliest stages of recurrent metastatic growth, mirroring what occurs during the 
primary tumor setting.  If this does indeed occur, we are uniquely situated to detect this 
phenomenon using GEDI.  If exercise delays or inhibits metastases, this may be 
reflected in CTC concentration. 
There are several strengths of this trial.  The use of two intervention groups, each 
prescribed a distinct dose of exercise will allow us examine how feasibility, safety, and 
physiologic effects differ along the exercise dose curve.  Given the eligibly criteria, these 
two different doses of exercise will require that some participants modestly increase their 
exercise and others to increase over 10-fold.  The exercise intervention was designed to 
allow for scalability to larger phase 2 and ultimately a phase 3 clinical trial.  The exercise 
program allows for flexibility, emphasizing a home-based program, blended with 
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supervised training and ongoing behavioral and clinical support from an exercise 
physiologist.  The provision of home-based treadmills serves a dual purpose of providing 
a reasonable incentive for participation, and promoting feasibility and favorable 
adherence to the exercise prescription over six months. 
There exist several limitations to this trial.  The primary limitation to this study is the 
small sample size which may limit interpretation of the study findings.  However, this 
study was designed to gather important feasibility, safety, and preliminary physiologic 
data to refine important design aspects for future phase 2 and phase 3 trials.  We 
acknowledge 300 min·wk-1 is a large weekly dose of aerobic exercise.  We elected to 
compare 150 and 300 min·wk-1 of aerobic exercise to complement ongoing work which 
prescribes 225 min·wk-1 [Courneya et al, 2008, Meyerhardt, 2013] and to parallel the 
epidemiologic data that suggest a dose-response relationship with disease outcomes 
[Campbell et al, 2013, Des Guetz et al, 2013, Je et al, 2013, Kuiper et al, 2012, 
Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009, Schmid and 
Leitzmann, 2014].  Our research team has been successful in promoting adherence to 
the prescription of 300 min·wk-1 of aerobic exercise in our prior studies [Schmitz et al, 
2015a, Schmitz et al, 2015b].  The high-dose exercise group received five additional in-
person sessions with the exercise physiologist which may differentially impact 
adherence rates between the low-dose and high-dose exercise groups.  Although VAT 
and fasting insulin are secondary outcomes of this trial, participants were not recruited 
on the basis of being overweight or obese at baseline and/or having high levels of 
fasting insulin.  Consequently this may limit our ability to detect significant exercise-
induced improvements in these outcomes.  We considered the inclusion of survivors of 
rectal cancer, but restricted inclusion to colon cancer survivors, as there is limited 
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evidence to support the benefit of exercise in improving rectal cancer outcomes 
[Meyerhardt et al, 2009]. 
Conclusion  
In conclusion, the findings from this trial will be useful in understanding the feasibility, 
safety, and physiologic effects of two doses of aerobic exercise among colon cancer 
survivors.  These findings contribute toward the goal of conducting a definitive trial to 
assess the effects of exercise on disease outcomes among colon cancer survivors. 
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Table 2.1 Demographic, clinical, and recruitment characteristics associated with study 
inquiry and randomization. 
Characteristic 
Invited to 
Participate 
(n=1,433) 
Inquired about Participation 
(n=126) 
Randomized 
(n=39) 
n (%) or 
Median [IQR] 
n (%) or 
Median 
[IQR] OR (95% CI)a P 
n (%) or 
Median 
[IQR] OR (95% CI)b P 
Age,c y 68 [58-77] 59 [53-59] 0.82 (0.76-0.88) <0.001 55 [47-61] 0.69 (0.60-0.78) <0.001 
<70 y 769 (54%) 95 (75%) 1.00  36 (92%) 1.00   
≥70 y 664 (46%) 31 (25%) 0.35 (0.23-0.53) <0.001 3 (8%) 0.09 (0.03-0.30) <0.001 
Sex, n (%)        
Male 710 (50%) 55 (44%) 1.00   15 (38%) 1.00   
Female 723 (50%) 71 (56%) 1.29 (0.90-1.87) 0.167 24 (62%) 1.59 (0.83-3.06) 0.164 
Race, n (%)        
White 1,086 (76%) 97 (77%) 1.00   31 (79%) 1.00   
Nonwhite 320 (22%) 29 (23%) 1.02 (0.66-1.57) 0.943 8 (21%) 1.59 (0.83-3.06) 0.164 
Missing or Unknown 27 (2%) 0 (0%) — — 0 (0%) — — 
Time Since Diagnosis,c 
mo 
16 [10-22] 16 [11-21]   15 [10-21]   
≤12 mo. 466 (32%) 37 (29%) 1.00   14 (36%) 1.00   
12-18 mo. 384 (27%) 36 (29%) 1.20 (0.74-1.94) 0.458 8 (20%) 0.69 (0.28-1.65) 0.403 
≥18 mo.  583 (41%) 53 (42%) 1.16 (0.75-1.80) 0.509 17 (44%) 0.97 (0.47-1.99) 0.933 
Anatomical Location, n 
(%) 
       
Left Colon 534 (38%) 57 (45%) 1.00   18 (46%) 1.00   
Right Colon 866 (60%) 67 (53%) 0.70 (0.48-1.02) 0.061 21 (54%) 0.71 (0.38-1.35) 0.298 
Unknown or Multiple 33 (2%) 2 (2%) 0.54 (0.13-2.31) 0.407 0 (0%) — — 
AJCC Stage,d n (%)        
I 349 (24%) 28 (22%) 1.00   5 (13%) 1.00   
II 523 (37%) 44 (35%) 1.05 (0.64-1.73) 0.838 14 (36%) 1.89 (0.67-5.30) 0.225 
III 561 (39%) 54 (43%) 1.22 (0.76-1.97) 0.412 20 (51%) 2.54 (0.95-6.84) 0.064 
Invasion Through Bowel 
Wall (T Stage), n (%) 
       
T1 247 (17%) 23 (18%) 1.00   4 (10%) 1.00   
T2 174 (12%) 10 (8%) 0.59 (0.27-1.28) 0.184 2 (5%) 0.71 (0.13-3.90) 0.690 
T3 773 (54%) 74 (59%) 1.03 (0.63-1.68) 0.903 25 (64%) 2.03 (0.70-5.89) 0.193 
T4 239 (17%) 19 (15%) 0.84 (0.44-1.59) 0.594 8 (21%) 2.10 (0.62-7.08) 0.230 
Lymph Node Involvement 
(N Stage), n (%) 
       
N0 (0) 872 (61%) 72 (57%) 1.00   19 (49%) 1.00   
N1 (1-3) 381 (27%) 34 (27%) 1.09 (0.71-1.67) 0.696 15 (38%) 1.84 (0.92-3.66) 0.082 
N2 (≥4) 180 (12%) 20 (16%) 1.39 (0.82-2.34) 0.219 5 (13%) 1.28 (0.47-3.48) 0.625 
Grade of Differentiation, n 
(%) 
       
Well (low) 123 (9%) 6 (5%) 1.00   2 (5%) 1.00   
Moderate 
(intermediate) 
940 (66%) 85 (67%) 1.94 (0.83-4.54) 0.127 29 (74%) 1.92 (0.45-8.17) 0.374 
Poor or 
Undifferentiated (high) 
275 (19%) 25 (20%) 1.94 (0.78-4.88) 0.154 5 (13%) 1.12 (0.21-5.85) 0.893 
Unknown 95 (6%) 10 (8%) 2.29 (0.80-6.56) 0.121 3 (8%) 1.97 (0.32-
12.05) 
0.462 
Lymphovascular 
Invasion, n (%) 
       
Absent  876 (61%) 73 (58%) 1.00   23 (59%) 1.00   
Present 391 (27%) 36 (29%) 1.11 (0.73-1.69) 0.609 12 (31%) 1.17 (0.58-2.38) 0.657 
Unknown 166 (12%) 17 (13%) 1.25 (0.72-2.19) 0.423 4 (10%) 0.91 (0.31-2.68) 0.872 
Chemotherapy, n (%) 709 (50%) 77 (61%) 1.68 (1.15-2.44) 0.007 28 (72%) 2.66 (1.32-5.39) 0.006 
Month Study Letter 
Mailed, n (%) 
       
January  865 (60%) 85 (67%) 1.00   31 (79%) 1.00   
March 100 (7%) 7 (6%) 0.69 (0.31-1.54) 0.365 1 (3%) 0.27 (0.04-2.01) 0.202 
May 119 (8%) 6 (5%) 0.49 (0.21-1.14) 0.098 2 (5%) 0.46 (0.11-1.94) 0.291 
July  349 (24%) 28 (22%) 0.80 (0.51-1.25) 0.328 5 (13%) 0.39 (0.15-1.01) 0.053 
Distance to Institution,c 
km 
20 [10-34] 21 [9-26] 1.03 (0.97-1.09) 0.327 20 [9-40] 1.07 (0.97-1.17) 0.182 
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aOdds Ratio (OR) and 95% Confidence Interval (CI) comparing those who inquired about participation to those who were invited to participate. 
bOdds Ratio (OR) and 95% Confidence Interval (CI) comparing those who were randomized to those who were invited to participate. 
cMedian and Interquartile [25-75%] range.   
dAJCC: American Joint Committee on Cancer (7th edition).    
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Figure 2.1 Study Schema  
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Figure 2.2 CONSORT Diagram 
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Abstract 
Background: Physical activity is associated with a lower risk of disease recurrence 
among colon cancer survivors.  Excess visceral adipose tissue (VAT) is associated with 
a higher risk of disease recurrence among colon cancer survivors.  The pathways 
through which physical activity alters disease outcomes are unknown, but may be 
mediated by changes in VAT. 
Methods: Between January 2015 and August 2015, 39 stage I-III colon cancer survivors 
were randomized to one of three groups: usual-care control, 150 min·wk-1 of aerobic 
exercise (low-dose), and 300 min·wk-1 of aerobic exercise (high-dose) for six months.  
The pre-specified key body composition outcome was VAT quantified using dual energy 
x-ray absorptiometry.  Other body composition outcomes were exploratory. 
Results: Exercise reduced VAT in dose-response fashion (Ptrend=0.008).  Compared to 
the control group, the low-dose and high-dose exercise groups lost 9.5 cm2 (95% CI: –
22.4, 3.5) and 13.6 cm2 (95% CI: –27.0, –0.1) in VAT, respectively.  Each 60 min·wk-1 
increase in exercise predicted a 2.7 cm2 (95% CI: –5.4, –0.1) reduction in VAT.  Exercise 
reduced waist circumference in dose-response fashion (Ptrend<0.001).  Compared to the 
control group, the low-dose and high-dose exercise groups lost 1.5 cm (95% CI: –4.0, 
1.1) and 4.5 cm (95% CI: −7.1, –1.9) in waist circumference, respectively.  Each 60 
min·wk-1 increase in exercise predicted a 0.9 cm (95% CI: –1.4, –0.4) reduction in waist 
circumference. 
Conclusion: Aerobic exercise reduces VAT in dose-response fashion among patients 
with stage I-III colon cancer.  Continued research to elucidate the mechanistic pathways 
through which physical activity alters disease outcomes is warranted. 
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Introduction  
Each year 83,000 people are diagnosed with non-metastatic colon cancer in the United 
States [Siegel et al, 2014].  Despite efficacious surgical and chemotherapeutic 
interventions, 25-40% will experience recurrent and metastatic disease within three-
years of diagnosis [André et al, 2004, Clinical Outcomes of Surgical Therapy Study 
Group, 2004, Quasar Collaborative Group, 2007], and 91% of those who recur within 
three-years, die by five-years [Sargent et al, 2005].  Therefore it is critical to study 
additional therapies that reduce the risk of recurrent disease and promote long-term 
survival in this population. 
Participation in physical activity after diagnosis of colon cancer is associated with a lower 
risk of recurrence and mortality [Meyerhardt et al, 2006].  This observation is 
independent of various demographic, clinico-pathologic, and treatment-related 
prognostic factors [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006, 
Meyerhardt et al, 2006, Meyerhardt et al, 2009].  A consistently reported observation is 
that post-diagnosis physical activity is associated with disease outcomes in a dose-
response fashion, such that larger doses of physical activity or exercise, up to 
approximately 300 minutes per week (min·wk-1), are associated with more favorable 
disease outcomes [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt et al, 2006, 
Meyerhardt et al, 2006, Meyerhardt et al, 2009]. 
The biologic or biobehavioral pathways through which exercise may favorably alter 
disease outcomes among colon cancer survivors are unknown.  One plausible pathway 
includes exercise-induced alterations in body composition [Parkin et al, 2014].  Excess 
visceral adipose tissue (VAT) is associated with an increased risk of disease recurrence 
and mortality among colon cancer survivors [Lee et al, 2015, Moon et al, 2008, Rickles 
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et al, 2013].  In addition, waist circumference (an anthropometric proxy for VAT) is 
associated with cancer-specific and all-cause mortality among colon cancer survivors 
[Haydon et al, 2006a].  These observations are further strengthened by evidence that 
the VAT of colon cancer survivors exhibits extensive metabolomic activity [Liesenfeld et 
al, 2015], and polymorphisms within adiposity-related genes predict disease recurrence 
among colon cancer survivors [Sebio et al, 2015]. 
Exercise reduces VAT among non-diabetic persons with obesity in a dose-response 
fashion [Slentz et al, 2005]; however the dose-response effects of exercise on VAT and 
other body composition measures, such as waist circumference, have not been 
examined among colon cancer survivors.  Understanding how exercise may alter 
pathways that are hypothesized to influence disease outcomes and the sensitivity of 
such pathways to respond to different doses of exercise will help to improve the 
specificity of exercise prescriptions in this population, and provide experimental evidence 
to support the findings of observational studies that document the benefits effects of 
exercise among colon cancer survivors. 
The COURAGE trial was a randomized controlled trial with the primary aim of examining 
the safety, feasibility, and biological efficacy of 150 and 300 min·wk-1 of aerobic exercise 
versus usual care control over six months among men and women with a history of non-
metastatic colon cancer [Brown et al, 2016].  Here we report body composition 
outcomes.  VAT quantified using dual-energy x-ray absorptiometry (DXA) was pre-
specified as the key body composition outcome of this trial.  Our hypothesis was that 
exercise would reduce VAT in a dose-response fashion. 
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Methods   
Participants  
Detailed study methods of the COURAGE trial were published previously [Brown et al, 
2016].  Potentially-eligible participants were recruited throughout the metropolitan 
Philadelphia region.  Participants were eligible if they: 1) were diagnosed with 
histologically-proven stage I-III colon cancer; 2) completed surgical resection and 
adjuvant chemotherapy within 36 months of entering the study; 3) self-reported 
participating in ≤150 min·wk-1 of moderate or vigorous intensity physical activity using the 
Paffenbarger Physical Activity Questionnaire [20]; 4) were of age ≥18 years; 5) provided 
written physician approval; 6) had no additional surgery planned within the six month 
intervention period (including colostomy reversal); 7) had the ability to walk unaided for 
six minutes.  Participants were ineligible if they: 1) had a history of another primary 
cancer (other than non-melanoma skin-cancer); 2) had evidence of metastatic cancer; 3) 
were pregnant or breast feeding; 4) were unable to provide a baseline blood sample; 5) 
had a myocardial infarction or coronary revascularization procedure within the past three 
months; 6) had uncontrolled hypertension, defined as a systolic blood pressure ≥180 
mm Hg or diastolic blood pressure ≥100 mm Hg; 7) had high-risk or uncontrolled heart 
arrhythmias (not including atrial fibrillation); 8) had clinically significant heart valve 
disease; 9) had decompensated heart failure; 10) had a known aortic aneurysm; or 11) 
had any other condition which, in the opinion of the investigator, may impede testing of 
study hypotheses or make it unsafe to engage in the exercise program. 
Participants were stratified on cancer stage (AJCC 7th Edition: I vs II vs III) and 
randomized into one of three groups: low-dose aerobic exercise (150 min·wk-1), high-
dose aerobic exercise (300 min·wk-1), or usual care control.  This study was approved by 
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the University of Pennsylvania Institutional Review Board.  Participants provided written 
informed consent and written approval from their physician prior to participation. 
Intervention 
Aerobic exercise was performed over six months using study-provided in-home 
treadmills (LifeSpan Fitness, TR1200i, Salt Lake City, UT).  Participants were provided 
with a heart rate monitor to objectively record heart rate during each exercise session.  
Participants also used exercise logs to record the date, time, average heart rate, and 
exercise duration.  Participants met with a clinical exercise physiologist to introduce the 
exercise prescription, and familiarize the participant with use of the treadmill, completion 
of exercise logs, use of a heart rate monitor, appropriate warm-up and cool-down, 
stretches, and proper footwear for aerobic exercise.  Participants were encouraged to 
individualize their frequency (days per week), fractionation (sessions per day), and 
duration (minutes per day) of exercise according to a schedule that promoted a high 
level of adherence to the prescribed exercise volume.  The exercise physiologist 
provided ongoing behavioral and clinical support and monitored exercise adherence to 
the study protocol throughout the duration of the study through the use of weekly 
telephone and email communications.  Exercise intensity was prescribed at 50-70% of 
the age-predicted maximum heart rate (3-6 METs [Ainsworth et al, 2000]).  The low-dose 
and high-dose groups progressed towards of the goal of 150 or 300 min·wk-1 of exercise, 
respectively.  Detailed methods of the exercise intervention were published previously 
[Brown et al, 2016]. 
Participants randomized into the usual-care control group were asked to maintain their 
pre-study levels of physical activity and/or follow the recommendations provided by their 
physician.  After completing six month measures, control group participants were 
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provided with an in-home treadmill and individualized exercise program, similar to that 
prescribed to the two exercise groups.  Upon study completion, all participants were 
allowed to keep their study-provided treadmills. 
Measurements 
Baseline and follow-up measurements were obtained by trained staff members who 
were blinded to treatment assignment.  Demographic characteristics including age, sex, 
race, and education were self-reported.  Smoking status was obtained from a 
standardized questionnaire [Pleis et al, 2009].  Daily caloric intake was quantified using 
three-day food records that were analyzed by a registered dietitian using the Nutrition 
Data System for Research software (v.2014).  Moderate to vigorous intensity physical 
activity was quantified using an accelerometer (ActiGraph GT3X+) with validated cut-
points [Troiano et al, 2008].  Clinical information including cancer stage, treatment with 
chemotherapy, and performance status were obtained from the Pennsylvania State 
Cancer Registry, pathology reports, or physician records.  Five-year predicted overall 
survival was calculated using a validated prognostic model for colon cancer [Weiser et 
al, 2011]. 
Body Composition Outcomes  
The pre-specified key body composition outcome was VAT quantified using DXA.  All 
other body composition outcomes were considered exploratory.  All participants 
underwent whole-body DXA (Hologic Horizon, Bedford MA).  All DXA scans were 
reviewed for quality assurance by a certified DXA technician who was blinded to study 
group [Powers et al, 2014].  The DXA scanner was calibrated daily using an 
anthropomorphic spine phantom and thrice weekly using a whole body phantom.  DXA 
was used to quantify VAT (cm2), subcutaneous adipose tissue (cm2), fat mass (kg), lean 
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mass (kg), and bone mineral density (g/m2) using Hologic APEX v.13.5 software.  DXA-
derived VAT has been validated against computed tomography-derived VAT (r=0.93; 
P<0.001) [Micklesfield et al, 2012], and has been used across a large body mass 
spectrum [Bredella et al, 2013].  Other anthropometric outcomes that were measured in 
duplicate included height (m), body mass (kg), waist & hip circumferences (cm), and 
sagittal abdominal diameter (cm).  Height and body mass were used to calculate body 
mass index (BMI; kg/m2). 
Statistical Analysis  
Descriptive statistics presented for baseline variables include counts and proportions for 
categorical variables and means ± standard deviations for continuous variables.  
Categorical baseline characteristics were compared among the three groups using 
Fisher’s exact test, and continuous baseline characteristics were compared among the 
three study groups using the Kruskal-Wallis test.  Based on prior research [Slentz et al, 
2005, Slentz et al, 2009, Slentz et al, 2004], we estimated a change in VAT of +14 cm2 
(+8.6%) in the control group, +2.9 cm2 (+1.7%) in the low-dose group, and –11.6 cm2 
(−6.9%) in the high-dose group with a pooled standard deviation of ±11 cm2 (±17%) over 
six months.  Against the hypothesis of a dose-response relationship, 39 participants 
provided ≥80% power with a type I error rate of 5% (α=0.05).  All inferential analyses 
were conducted on an intention-to-treat basis.  Change in VAT (and other outcomes) 
was evaluated from baseline to six months in the three groups using repeated-measures 
mixed-effects regression models.  This statistical approach includes all available data 
and accounts for the correlation between repeated measures.  The baseline value of the 
dependent variable and cancer stage (randomization stratification factor) were included 
as covariates in the regression models [Fitzmaurice et al, 2004].  Group-by-time 
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interaction terms were estimated as fixed-effects in the regression model.  Results from 
the repeated-measures mixed-effects regression models are presented as least-square 
means (LS Mean) ± standard error (SE).  To evaluate the presence of a dose-response 
relationship across randomized groups, a test of trend was conducted by examining 
linear contrasts.  All statistical analyses were completed using Stata/MP Version 14.1 
(StataCorp, College Station, TX). 
Results  
Between January 2015 and August 2015, 39 colon cancer survivors were recruited and 
randomized with data collection ending in February 2016.  Baseline characteristics of 
study participants are presented in Table 3.1.  Age ranged from 35–81 years.  BMI 
ranged from 20–43 kg/m2; 51% of participants were obese (BMI ≥30 kg/m2).  
Objectively-measured moderate to vigorous intensity physical activity ranged from 3–34 
min·d-1; 61% of participants self-reported not participating in any physical activity since 
their colon cancer diagnosis.  Time since finishing colon cancer treatment ranged from 
1–21 months.  Five-year predicted overall survival ranged from 35–92%.  Figure 3.1 
shows the flow of the 39 randomized participants through the study.  One participant 
was lost to follow-up (97% follow-up rate). 
Exercise prescription program variables are presented in Table 3.2.  Over six months, 
adherence to the prescribed volumes of exercise in the low-dose and high-dose groups 
were 92.8±2.44% and 89.0±2.64%, respectively (P=0.287).  Average exercise volume in 
the low-dose and high-dose groups were 141.5±9.92 min·wk-1 and 247.2±10.71 min·wk-
1, respectively (∆ between groups: 105.7±14.60; P<0.001).  The high-dose group 
exercised on more days per week (P=0.001), more sessions per day (P=0.001), longer 
duration per session (P<0.001), and required more weeks to progress to the full dose of 
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prescribed exercise (P=0.007), as compared to the low-dose group.  Exercise intensity 
was 70.7±0.85% of the age-predicted maximal heart rate, the proportion of exercise 
sessions using the study-provided treadmill was 76.5±9.4%, and the proportion of 
exercise sessions validated with objective heart rate data was 96.8±0.59%, all of which 
did not differ between the two exercise groups.  Accelerometer-quantified moderate to 
vigorous intensity physical activity increased in dose-response fashion (Ptrend<0.001); 
over six months the control group increased by 4.2±6.5 min·d-1, whereas the low-dose 
and high-dose groups increased by 26.5±6.1 and 33.1±6.5 min·d-1, respectively. 
Body composition outcomes are presented in Table 3.3.  At baseline, no differences in 
body composition were observed among the three groups.  Exercise reduced VAT, the 
pre-specified key body composition outcome, in dose-response fashion (Ptrend=0.008; 
Figure 3.2A).  Compared to the control group, the low-dose and high-dose exercise 
groups lost 9.5 cm2 (95% CI: –22.4, 3.5) and 13.6 cm2 (95% CI: –27.0, –0.1) in VAT, 
respectively.  Each 60 min·wk-1 increase in exercise predicted a 2.7 cm2 (95% CI: –5.4, –
0.1) reduction in VAT.  This finding was reinforced by the observation that exercise 
reduced waist circumference (an anthropometric proxy for VAT) in dose-response 
fashion (Ptrend<0.001; Figure 3.2B).  Compared to the control group, the low-dose and 
high-dose exercise groups lost 1.5 cm (95% CI: –4.0, 1.1) and 4.5 cm (95% CI:–7.1, –
1.9) in waist circumference, respectively.  Each 60 min·wk-1 increase in exercise 
predicted a 0.9 cm (95% CI: –1.4, –0.4) reduction in waist circumference.  Changes in 
VAT were correlated with changes in waist circumference (r=0.42; P=0.009).  
Improvements in waist-to-hip ratio were of marginal significance (Ptrend=0.054).  An 
unexpected finding was the observed improvement in bone mineral density 
(Ptrend=0.015).  Compared to the control group, the low-dose and high-dose exercise 
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groups gained 0.015 g/m2 (95% CI: 0.001, 0.029) and 0.013 g/m2 (95% CI: -0.001, 0.028) 
in bone mineral density, respectively.  This improvement was not hypothesized to occur 
and bone mineral density was an exploratory outcome; therefore, this finding should be 
viewed as hypothesis generating and may be a type I error (false positive).  No 
significant change in body mass was observed (Ptrend=0.280), this was expected 
because self-reported caloric consumption did not change (Ptrend=0.743).  No serious 
(grade ≥3) adverse events occurred. 
 
Discussion  
A six month moderate-intensity aerobic exercise program among stage I-III colon cancer 
survivors resulted in significant linear dose-response reductions in VAT measured by 
DXA and waist circumference.  The findings from this randomized trial provide 
mechanistic data to support observational evidence that suggests physical activity may 
lower the risk of recurrence and mortality among colon cancer survivors. 
The linear reductions in VAT and waist circumference with increasing exercise volume 
are similar to prior dose-response exercise interventions in other populations (reviewed 
here [Kay and Singh, 2006]).  For example, among overweight and obese men and 
women with dyslipidemia, increasing exercise volume was associated with larger 
reductions in VAT [Slentz et al, 2005], and waist circumference [Slentz et al, 2004].  In 
our study, the usual-care control group increased VAT and waist circumference over six 
months.  This observation has been reported in the control groups of prior exercise trials 
[Slentz et al, 2005, Slentz et al, 2004], and underscores the deleterious effect of 
continued sedentary behavior.  Excess energy is preferentially stored as VAT during 
extended periods of inactivity [Belavý et al, 2014].  It is also important to note that we did 
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not observe significant changes in body mass.  Exercise preferentially utilizes VAT as an 
energetic substrate, often without altering total body mass [Johnson et al, 2009, Lee et 
al, 2005].  Healthcare providers who prescribe exercise to colon cancer survivors should 
inform patients that exercise may not significantly reduce body mass, and that body 
mass alone should not be used as an indicator of exercise success, as important 
physiologic changes are likely to occur in the absence of weight loss. 
The biologic or biobehavioral pathways through which exercise may favorably alter 
disease outcomes among colon cancer survivors are unknown.  Excess VAT and waist 
circumference are associated with an increased risk of disease recurrence and mortality 
among colon cancer survivors [Haydon et al, 2006a, Lee et al, 2015, Moon et al, 2008, 
Rickles et al, 2013].  VAT is an active endocrine organ that secretes various bioactive 
compounds such as adipokines, cytokines, hormone-like factors, and other metabolites 
[Ahima and Flier, 2000, Balistreri et al, 2010, Liesenfeld et al, 2015] that have been 
hypothesized to influence disease recurrence and progression [Park et al, 2014].  
Excess VAT and other states associated with adiposity such as hyperinsulinemia 
activate the PI3K-Akt-mTOR pathway [McCurdy and Klemm, 2013].  Activation of the 
PI3K-Akt-mTOR pathway is associated with the growth and progression of colon cancer 
metastases [Gulhati et al, 2011], and silencing of this pathway inhibits the growth of 
metastases by inducing cell-cycle arrest and apoptosis [Zhang et al, 2009].   Several 
polymorphisms within adiposity-related genes predict disease recurrence among colon 
cancer survivors [Sebio et al, 2015].  For example, PPAR-γ rs1801282 regulates 
transcription factors for several genes that influence colon cancer growth [Sarraf et al, 
1998].  Furthermore, PPAR-γ rs1801282 predicts the progression from impaired glucose 
tolerance to type 2 diabetes [Brito et al, 2009, Kilpelainen et al, 2008].  Participation in 
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physical activity significantly reduces the risk of progression from impaired glucose 
tolerance to type 2 diabetes that is associated with this polymorphism [Brito et al, 2009, 
Kilpelainen et al, 2008].  Type 2 diabetes is associated with a worsened prognosis in 
colon cancer [Jeon et al, 2013, Meyerhardt et al, 2003].  Future research will be needed 
to discern if the disease-specific benefits of physical activity for colon cancer survivors 
are achieved through similar pathways. 
There are several limitations to this trial.  The primary limitation to this trial is the small 
sample size, which limited our statistical power to examine other body composition 
outcomes.  The small sample size also reduces the generalizability of our findings.  As 
we have previously described [Brown et al, 2016], trial participants were younger than 
the population from which they were recruited.  This has important implications for the 
generalizability of our findings to the broader population of colon cancer survivors.  The 
duration of the exercise intervention was six months, which is modest relative to other 
trials of 12 to 36 months.  It is unknown if the dose-response effects of exercise on VAT 
are maximized or sustained over longer periods of time.  Trial participants were not 
recruited on the basis of having high levels of VAT.  It is unknown if the exercise-induced 
reductions in VAT would be similar or larger in magnitude among a sample with high 
levels of VAT at baseline. 
There are several strengths to this trial.  The use of two intervention groups, each 
prescribed a distinct dose of exercise, allowed us examine how VAT responded along 
the exercise dose curve.  The exercise program was flexible, emphasizing a home-
based program, blended with ongoing behavioral and clinical support from an exercise 
physiologist.  The provision of home-based treadmills succeeded in providing a 
reasonable incentive for participation as recruitment was completed ahead of schedule, 
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and succeeded in promoting favorable adherence to the exercise prescription over six 
months.  Completion of the prescribed exercise dose was objectively quantified using 
heart-rate monitors with long-term (≥3 month) memory.  Data collection was completed 
by staff blinded to study group who followed standardized protocols.  Participants in this 
trial had later stage of disease than the population from which they were recruited 
[Brown et al, 2016], which represents colon cancer survivors at highest risk for disease 
recurrence.  Participants had a variety of comorbid conditions that are common among 
colon cancer survivors including hypertension, hyperlipidemia, diabetes, and 
cardiovascular disease.  Endpoint data collection was satisfactory (97% complete). 
In conclusion, the findings from this randomized trial demonstrate the dose-response 
effects of moderate intensity aerobic exercise to favorably reduce VAT among selected 
patients recently treated for stage I-III colon cancer.  The findings from this randomized 
trial may be useful to healthcare providers to improve the specificity of exercise 
prescriptions for colon cancer survivors.  The findings from this randomized trial are also 
useful to investigators to begin to understand the mechanistic pathways that are 
hypothesized to mediate the relationship between exercise and disease outcomes in this 
population.  Continued research to elucidate the mechanistic pathways through which 
physical activity alters disease outcomes is warranted. 
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Table 3.1 Baseline characteristics of the participants  
Characteristic 
Total
(n=39) 
Control
(n=13) 
Low-Dose
(n=14) 
High-Dose
(n=12) P
Age, years 56.5±10.0 57.9±9.7 58.2±9.8 53.1±10.5 0.493 
Sex, %      
Male 15 (38%) 4 (31%) 7 (50%) 4 (33%) 0.601 
Female 24 (62%) 9 (69%) 7 (50%) 8 (67%)  
Race, %      
White 31 (80%) 8 (62%) 12 (86%) 11 (92%) 0.332 
Black 6 (15%) 3 (23%) 2 (14%) 1 (8%)  
Other 2 (5%) 2 (15%) 0 (0%) 0 (0%)  
Education, %      
High School or Less 7 (18%) 1 (8%) 4 (29%) 2 (17%) 0.765 
Some College 8 (20%) 3 (23%) 2 (14%) 3 (25%)  
College Degree or More 24 (62%) 9 (69%) 8 (57%) 7 (58%)  
Smoking History, %      
Never 23 (59%) 10 (77%) 6 (43%) 7 (58%) 0.407 
Former 14 (36%) 3 (23%) 7 (50%) 4 (33%)  
Current 2 (5%) 0 (0%) 1 (7%) 1 (8%)  
Caloric Consumption, kcal·d-1 1747±542 1749±545 1816±569 1665±543 0.725 
Moderate or Vigorous Physical 
Activity, min·d-1 
15.7±8.7 12.2±8.1 18.8±9.6 15.7±7.3 0.175 
Body Mass Index, kg·m-2 30.3±5.8 29.2±6.0 29.5±4.3 32.4±6.9 0.408 
Stage, %      
I 5 (13%) 1 (8%) 2 (14%) 2 (17%) 0.999 
II 14 (36%) 5 (38%) 5 (36%) 4 (33%)  
III 20 (51%) 7 (54%) 7 (50%) 6 (50%)  
Chemotherapy, % 28 (72%) 10 (77%) 10 (71%) 8 (67%) 0.906 
Time Since Treatment 
Completion, Months 
10.9±6.1 11.3±6.7 8.8±5.8 11.3±5.7 0.417 
ECOG Performance Status, %      
0, Fully active 29 (74%) 10 (77%) 9 (64%) 10 (83%) 0.595 
1, Ambulatory, but restricted in 
strenuous activity 
10 (26%) 3 (23%) 5 (36%) 2 (17%)  
Comorbid Conditions, %      
Hypertension 13 (33%) 4 (31%) 6 (43%) 3 (25%) 0.695 
Hyperlipidemia 6 (15%) 1 (8%) 2 (14%) 3 (25%) 0.480 
Type 2 Diabetes 5 (13%) 1 (8%) 1 (7%) 3 (25%) 0.409 
Cardiovascular Disease 4 (10%) 2 (15%) 1 (7%) 1 (8%) 0.827 
5-Year Predicted Survival, % 68 [60-87] 68 [61-85] 71 [60-88] 65 [60-83] 0.713 
P values are from the overall test of group differences.   
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Table 3.2 Exercise prescription program variablesa  
Characteristic 
Low-Dose
(n=14) 
High-Dose
(n=12) 
∆ Between Groups
(LS Mean ± SE) P
Frequency (days of exercise per week) 3.5±0.15 4.3±0.16 0.75±0.22 0.001 
Fractionization (sessions of exercise per 
day) 
1.1±0.07 1.4±0.07 0.31±0.10 0.001 
Intensity (% of heart rate maximum) 71.6±1.16 69.6±1.27 -1.89±1.72 0.272 
Time (minutes of exercise per day) 41.6±2.38 59.1±2.57 17.4±3.50 <0.001 
Type (% of exercise sessions using 
treadmill) 
72.3±12.9 81.3±15.5 8.0±18.71 0.669 
Volume (minutes of exercise per week) 141.5±9.92 247.2±10.71 105.7±14.60 <0.001 
Progression (weeks to full dose of 
exercise)b 
4 [4-5] 8 [7-10] 4 [2-6] 0.007 
% of exercise confirmed with HRM 97.3±0.81 96.2±0.87 -1.1±1.19 0.344 
% adherence to prescribed exercise 
dose 
92.8±2.44 89.0±2.64 -3.8±3.60 0.287 
% with ≥80% adherence, n (%) 12 (86%) 9 (75%) -10.6±15.2 0.488 
MET hours per weekc  13.7±0.96 23.9±1.03 10.2±1.41 <0.001 
aData are least squares mean (LS Mean) ± standard error (SE) unless otherwise noted. bMedian 
[interquartile 25-75% range]. cCalculated using available treadmill speed and incline, and averaged across 
all exercise sessions.   
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Table 3.3 Body composition outcomes at baseline and change during six months 
Outcome 
Baseline
(Mean ± SD) 
∆ Baseline to Month 6
(LS Mean ± SE) 
∆ from Control
(LS Mean ± SE) 
Body Mass, kg    
Control 83.7±22.1 0.43±0.61 — 
Low-Dose 86.2±13.1 −0.51±0.57 −0.95±0.84 
High-Dose 92.2±24.3 −0.32±0.62 −0.76±0.87 
Test for trend  P=0.280  
BMI, kg/m2 
Control 29.2±6.0 0.14±0.22 — 
Low-Dose 29.5±4.3 −0.17±0.21 −0.31±0.30 
High-Dose 32.5±6.9 −0.11±0.23 −0.25±0.32 
Test for trend  P=0.354  
Waist Circumference, cm    
Control 98.0±17.1 1.62±0.94 — 
Low-Dose 98.7±11.9 0.16±0.89 −1.46±1.29 
High-Dose 106.9±14.6 −2.90±0.96a −4.52±1.34b
Test for trend  P<0.001  
Hip Circumference, cm    
Control 103.4±13.5 1.85±1.42 — 
Low-Dose 104.5±10.3 0.18±1.34 −1.67±1.95 
High-Dose 110.6±15.0 0.02±1.45 −1.84±2.03 
Test for trend  P=0.518  
Waist to Hip Ratio    
Control 0.94±0.09 −0.005±0.011 — 
Low-Dose 0.94±0.07 0.001±0.011 0.005±0.016 
High-Dose 0.97±0.09 −0.029±0.012a −0.023±0.016 
Test for trend  P=0.054  
Sagittal Abdominal Diameter, cm   
Control 22.6±4.0 0.45±0.32 — 
Low-Dose 22.4±3.6 0.01±0.30 −0.43±0.44 
High-Dose 23.9±4.0 0.01±0.32 −0.45±0.46 
Test for trend  P=0.200  
Visceral Adipose Tissue, cm2    
Control 112.6±55.2 5.31±4.80 — 
Low-Dose 131.3±45.6 −4.13±4.53 −9.45±6.60 
High-Dose 154.2±60.5 −8.27±4.89 −13.58±6.86b
Test for trend  P=0.008  
Subcutaneous Adipose Tissue, 
cm2 
   
Control 388.4±142.6 −3.87±8.64 — 
Low-Dose 381.1±138.6 1.70±8.15 5.57±11.88 
High-Dose 461.9±110.9 −17.86±8.81a −14.00±12.34 
Test for trend  P=0.222  
Fat Mass, kg 
Control 32.8±10.0 −0.01±0.49 — 
Low-Dose 32.6±7.6 −0.13±0.47 −0.12±0.68 
High-Dose 38.1±11.9 −0.71±0.50 −0.70±0.71 
Test for trend  P=0.238  
Lean Mass, kg 
Control 49.9±13.1 0.30±0.35 — 
Low-Dose 52.6±11.1 −0.06±0.33 −0.36±0.48 
High-Dose 53.4±13.8 0.01±0.36 −0.29±0.50 
Test for trend  P=0.450  
Bone Mineral Density, g/cm2    
Control 1.08±0.10 0.006±0.005 — 
Low-Dose 1.03±0.12 0.021±0.005a 0.015±0.007b 
High-Dose 1.02±0.09 0.020±0.005a 0.013±0.007 
Test for trend  P=0.015  
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SD, standard deviation; LS Mean, least squares mean; SE, standard error.  aSignifcantly different from 
baseline (within-group), P≤0.05.  bSignificantly different from control, P≤0.05.   
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Figure 3.1 Flow of participants through the study 
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Figure 3.2 Between group changes in A) visceral adipose tissue and B) waist 
circumference from baseline to six months  
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A 
Linear trend, P=0.008 
 
B 
Linear trend, P<0.001 
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Abstract 
Background: Physical activity is associated with a lower risk of disease recurrence 
among colon cancer survivors.  The pathways through which physical activity alters 
disease outcomes are unknown, but may be mediated by changes in metabolic growth 
factors, such as insulin. 
Methods: Between January 2015 and August 2015, 39 stage I-III colon cancer survivors 
were randomized to one of three groups: usual-care control, 150 min·wk-1 of aerobic 
exercise (low-dose), and 300 min·wk-1 of aerobic exercise (high-dose) for six months.  
The pre-specified key metabolic growth factor outcome was fasting insulin.  Insulin 
resistance was quantified using the homeostatic model assessment. 
Results: Mean age was 56.5±10.0 years, 51% had stage III disease, 72% were treated 
with chemotherapy, and the mean time since finishing treatment was 10.9±6.1 months. 
Over six months, the low-dose group completed a mean 141.5±9.9 min·wk-1 of aerobic 
exercise, and the high-dose group completed a mean 247.2±10.7 min·wk-1 of aerobic 
exercise.  Fasting insulin concentrations decreased 7.4±9.4 pmol/L in the control group, 
28.0±8.3 pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group 
(nonlinear Ptrend=0.042).  Insulin resistance decreased 0.11±0.20 in the control group, 
0.63±0.17 in the low-dose group, and 0.43±0.19 in the high-dose group (nonlinear 
Ptrend=0.012).   
Discussion: Aerobic exercise reduces insulin concentrations and insulin resistance 
among patients with stage I-III colon cancer.  Prescribing 150 min·wk-1 of aerobic 
exercise may be sufficient for reducing insulin concentrations and insulin resistance, 
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which may partially mediate the relationship between physical activity and colon cancer 
prognosis. 
Introduction  
Each year more than 103,000 people are diagnosed with colon cancer in the United 
States [Siegel et al, 2015]. Approximately three-quarters of patients will be diagnosed 
with disease that is localized to the primary site (stage I-II) or spread to regional lymph 
nodes (stage III).  Despite surgical resection, either alone or in combination with 
adjuvant chemotherapy, five-year recurrence rates for patients with stage I, II, and III 
colon cancer are 10%, 20%, and 30-50%, respectively [André et al, 2004, Clinical 
Outcomes of Surgical Therapy Study Group, 2004, Quasar Collaborative Group, 2007].  
Consequently, there exists a need to identify additional adjuvant therapies that reduce 
the risk of recurrent disease in this population. 
The prescription of physical activity or exercise is a potential adjuvant therapy that has 
been reported in multiple observational studies to be associated with a reduction in the 
risk of recurrence and death among colon cancer survivors [Campbell et al, 2013, Kuiper 
et al, 2012, Meyerhardt et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009].  The 
relationship between physical activity and disease outcomes is independent of known 
prognostic factors, and occurs in a dose-response fashion, such that higher volumes of 
physical activity or exercise, up to 300 minutes per week (min·wk-1), are associated with 
more favorable disease outcomes [Campbell et al, 2013, Kuiper et al, 2012, Meyerhardt 
et al, 2006, Meyerhardt et al, 2006, Meyerhardt et al, 2009]. 
The biologic or biobehavioral pathways through which exercise may favorably alter colon 
cancer outcomes have not been elucidated, but may include exercise-induced 
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alterations in metabolic growth factors, such as insulin, C-peptide, insulin-like growth 
factor-1 (IGF-1), and insulin-like growth factor-binding protein-3 (IGFBP-3).  Colon 
cancer cells have insulin/IGF-1 receptors on their surface [Belfiore and Malaguarnera, 
2011] and insulin/IGF-1 promote colon cancer cell proliferation and inhibit apoptosis 
[Koenuma et al, 1989].  In vitro studies demonstrate that states of hyperinsulinemia 
increase colon cancer cell resistance to 5-fluorouracil [Chen et al, 2011b] and oxaliplatin 
chemotherapy [Chen et al, 2011a, Volkova et al, 2014].  Preclinical models demonstrate 
that exposure to insulin promotes colonic tumor multiplicity [Tran et al, 1996].  Elevated 
levels of C-peptide and lower levels of IGFBP-3 are associated with a higher risk of 
death among men and women with colon cancer [Haydon et al, 2006b, Wolpin et al, 
2009].  Together, this evidence supports the hypothesis that insulin and IGF-1 may be 
important mediators of the relationship between exercise and disease outcomes among 
colon cancer survivors. 
Colon cancer survivors have fasting insulin concentrations that are 58% higher than 
healthy controls without a history of colon cancer [Jiang et al, 2014].  A pilot study of 17 
colon cancer survivors demonstrated that a three-month prescription of exercise reduced 
insulin and increased IGF-1 and IGFBP-3 concentrations [Lee et al, 2013].  However, no 
randomized trials have examined the dose-response effects of exercise on metabolic 
growth factors among colon cancer survivors. 
These observations provided the scientific rationale for the COURAGE trial, a randomized 
controlled trial investigating the safety, feasibility, and biological efficacy of 150 and 300 
min·wk-1 of aerobic exercise versus usual care control over six months among men and 
women recently-treated for stage I-III colon cancer [Brown et al, 2016].  Here we report 
on fasting insulin as the pre-specified key metabolic growth factor of interest.  We have 
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previously demonstrated that visceral adipose tissue is reduced with exercise [Brown et 
al, to be submitted].  As an exploratory aim of this report, we characterized the 
relationship between changes in visceral adipose tissue with changes in fasting insulin.  
Our hypotheses were that: 1) exercise would reduce fasting insulin concentrations in a 
dose-response fashion; and 2) reductions in visceral adipose tissue would correlate with 
reductions in fasting insulin. 
Methods  
Participants  
Study methods of the COURAGE trial were published [Brown et al, 2016].  Participants 
were recruited from the metropolitan Philadelphia region and surrounding counties.  
Participants were eligible if they: 1) were diagnosed with histologically-proven stage I-III 
colon cancer; 2) completed surgical resection and adjuvant chemotherapy within 36 
months of entering the study; 3) self-reported participating in ≤150 min·wk-1 of moderate 
or vigorous intensity physical activity using the Paffenbarger Physical Activity 
Questionnaire [20]; 4) were of age ≥18 years; 5) provided written physician approval; 6) 
had no additional surgery planned within the six month intervention period (including 
colostomy reversal); and 7) had the ability to walk unassisted for six-minutes.  
Participants were ineligible if they: 1) had a history of another primary cancer (other than 
non-melanoma skin-cancer); 2) had evidence of metastatic cancer; 3) were pregnant or 
breast feeding; 4) were unable to provide a baseline blood sample; 5) had a myocardial 
infarction or coronary revascularization procedure within the past three months; 6) had 
uncontrolled hypertension, defined as a systolic blood pressure ≥180 mm Hg or diastolic 
blood pressure ≥100 mm Hg; 7) had high-risk or uncontrolled heart arrhythmias (not 
including atrial fibrillation); 8) had clinically significant heart valve disease; 9) had 
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decompensated heart failure; 10) had a known aortic aneurysm; or 11) had any other 
condition which, in the opinion of the investigator, may impede testing of the study 
hypothesis or make it unsafe to engage in the exercise program. 
Participants were stratified by cancer stage (AJCC 7th Edition: I vs II vs III) and 
randomized into one of three groups: low-dose aerobic exercise (150 min·wk-1), high-
dose aerobic exercise (300 min·wk-1), or usual care control.  This study was approved by 
the University of Pennsylvania Institutional Review Board.  All participants provided 
written informed consent and written approval from their physician prior to participation in 
any study-related activities. 
Intervention 
Participants randomized to the low-dose or high-dose exercise groups were provided 
with an in-home treadmill (LifeSpan Fitness, TR1200i, Salt Lake City, UT) to promote 
exercise adherence, and a heart rate monitor (Polar Electro, RS400, Kempele Finland) 
to objectively record exercise intensity and duration.  Participants also documented their 
exercise in a written log book.  Exercise intensity was prescribed at 50-70% of the age-
predicted maximum heart rate (3-6 METs [Ainsworth et al, 2000]).  The low-dose and 
high-dose groups progressed towards of the goal of 150 or 300 min·wk-1 of exercise, 
respectively.  Participants met with a certified clinical exercise physiologist to introduce 
the exercise prescription, and familiarize the participant with use of the treadmill, 
completion of exercise logs, use of a heart rate monitor, appropriate warm-up and cool-
down, stretches, and proper footwear for aerobic exercise.  Participants were 
encouraged to individualize their frequency (days per week), fractionation (sessions per 
day), and duration (minutes per day) of exercise according to a schedule that promoted 
a high level of adherence to the prescribed exercise volume.  The exercise physiologist 
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provided ongoing behavioral and clinical support and monitored exercise adherence to 
the study protocol throughout the duration of the study.  Detailed methods of the 
exercise intervention were published [Brown et al, 2016]. 
Participants randomized to the usual-care control group were asked to maintain their 
pre-study levels of physical activity or follow the recommendations provided by their 
physician.  After completing six month measures, control group participants were 
provided with an in-home treadmill and individualized exercise program, similar to that 
prescribed to the two exercise groups.  Upon completion of study-related activities, all 
participants were allowed to keep their study-provided treadmills. 
Measurements 
Baseline and follow-up measurements were obtained by trained staff members who 
were blinded to treatment assignment.  Demographic characteristics including age, sex, 
race, and education were self-reported.  Smoking status was obtained from a 
standardized questionnaire [Pleis et al, 2009].  Daily caloric intake and the proportion of 
calories from carbohydrate sources were quantified using three-day food records that 
were analyzed using the Nutrition Data System for Research software (v.2014) by a 
registered dietitian who was blinded to study group.  Moderate to vigorous intensity 
physical activity was quantified using an accelerometer (ActiGraph GT3X+) with cut-
points appropriate for adults [Troiano et al, 2008].  Clinical information including cancer 
stage, treatment with chemotherapy, and performance status were obtained from the 
Pennsylvania State Cancer Registry, pathology reports, and physician records.  Five-
year predicted overall survival was calculated using a validated prognostic model for 
colon cancer [Weiser et al, 2011].  Body mass index (BMI; kg/m2) was calculated using 
standard anthropometric measures [weight (kg) and height (m)], and dual-energy x-ray 
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absorptiometry was used to quantify visceral adipose tissue, as previously described 
[Brown et al, 2016]. 
Metabolic Growth Factor Outcomes  
All study participants underwent a fasting blood draw at baseline and follow-up.  EDTA-
preserved plasma was stored at −80°C.  Insulin and C-peptide concentrations were 
quantified using a radioimmunoassay (EMD Millipore, Billerica, MA).  IGF-1, IGFBP-3, 
and fructosamine concentrations were quantified using an enzyme-linked 
immunosorbent assay (DSL, Webster, TX).  Glucose concentrations were quantified 
spectrophotometrically (Roche, Indianapolis, IN).  Baseline and follow-up plasma 
samples were assayed simultaneously and in duplicate at the end of the study.  
Coefficients of variation for all samples were ≤10%.  The homeostatic model assessment 
(HOMA) was used to quantify insulin resistance [Levy et al, 1998]. 
Statistical Analysis  
Descriptive statistics presented for baseline variables include counts and proportions for 
categorical variables and means ± standard deviations for continuous variables.  
Categorical baseline characteristics were compared among the three groups using 
Fisher’s exact test, and continuous baseline characteristics were compared among the 
three study groups using the Kruskal-Wallis test.  Based on prior research [Houmard et 
al, 2004], we estimated a mean change in fasting insulin concentrations of +6.6 pmol/L 
in the control group, −3.3 pmol/L in the low-dose group, and −5.9 pmol/L in the high-
dose group with a pooled standard deviation of ±4.6 pmol/L over six months.  Against 
the hypothesis of a dose-response relationship, 39 participants provided 80% power with 
a type I error rate of 5% (α=0.05).  All inferential analyses were conducted on an 
intention-to-treat basis.  Dependent variables were log transformed in the inferential 
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analysis to improve normality and back transformed to facilitate interpretation.  Changes 
were evaluated from baseline to follow-up in the three groups using repeated-measures 
mixed-effects regression models.  This statistical approach includes all available data 
and accounts for the correlation between repeated measures.  The baseline value of the 
dependent variable and cancer stage (randomization stratification factor) were included 
as covariates in the regression models [Fitzmaurice et al, 2004].  Group-by-time 
interaction terms were included as fixed-effects in the regression model.  Results from 
the repeated-measures mixed-effects regression models are presented as least-square 
means ± standard error.  To evaluate the presence of a dose-response relationship 
across randomized groups, a test of trend was conducted by examining linear and 
nonlinear (quadratic) contrasts.  Linear regression models were used to characterize 
changes in visceral adipose tissue with changes in growth factor concentrations from 
baseline to six months.  All statistical analyses were completed using Stata/MP Version 
14.1 (StataCorp, College Station, TX). 
Results  
Between January 2015 and August 2015, 39 colon cancer survivors were recruited and 
randomized with data collection ending in February 2016.  Baseline characteristics of 
study participants are presented in Table 4.1.  Age ranged from 35–81 years.  BMI 
ranged from 20–43 kg/m2; 31% of participants were overweight (BMI 25.0–29.9 kg/m2) 
and 51% were obese (BMI≥30 kg/m2).  Time since finishing colon cancer treatment 
ranged from 1–21 months.  Five-year predicted overall survival ranged from 35–92%.  
Five participants had type 2 diabetes mellitus at baseline, all were diagnosed ≥3 years 
prior to study enrollment, and all were using metformin (one as monotherapy, four as 
combination therapy with a sulfonylurea or DPP-4 inhibitor).  Figure 4.1 shows the flow 
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of the 39 randomized participants through the study.  One participant was lost to follow-
up. 
 Exercise prescription program variables are presented in Table 4.2.  Over six months, 
the average exercise volumes in the low-dose and high-dose groups were 141.5±9.92 
min·wk-1 (92.8±2.44% of prescribed dose) and 247.2±10.71 min·wk-1 (89.0±2.64% of 
prescribed dose), respectively.  The high-dose group completed on average an 
additional 105.7±14.60 min·wk-1 of exercise than the low-dose group (P<0.001).  
Exercise intensity was 70.7±0.85% of the age-predicted maximal heart rate and did not 
differ between groups (P=0.272).  The proportion of exercise sessions validated with 
objective heart rate data was 96.8±0.59% and did not differ between groups (P=0.344).  
Accelerometer-quantified moderate to vigorous intensity physical activity increased in 
dose-response fashion (linear Ptrend<0.001); over six months the control group increased 
by 4.2±6.5 min·d-1, whereas the low-dose and high-dose groups increased by 26.5±6.1 
and 33.1±6.5 min·d-1, respectively.  Daily caloric intake and the proportion of daily 
calories from carbohydrate sources were not significantly different from baseline in any 
of the groups (data not shown). 
Metabolic growth factor concentrations are presented in Table 4.3.  At baseline, no 
differences were observed among the three groups.  Fasting insulin concentration, the 
key growth factor outcome, decreased 7.4±9.4 pmol/L in the control group, 28.0±8.3 
pmol/L in the low-dose group, and 20.7±9.3 pmol/L in the high-dose group (nonlinear 
Ptrend=0.042; Figure 4.2).  Similarly, insulin resistance decreased 0.11±0.20 in the 
control group, 0.63±0.17 in the low-dose group, and 0.43±0.19 in the high-dose group 
(nonlinear Ptrend=0.012).  Fasting glucose concentration decreased in the low-dose 
group, whereas no difference was observed high-dose and control groups (nonlinear 
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Ptrend=0.004).  IGF-1, IGFBP-3, fructosamine, and C-peptide did not change in any of the 
study groups.  Adjustment for type 2 diabetes mellitus as a covariate in the regression 
models did not substantively alter the above-described findings.  No serious (grade ≥3) 
adverse events occurred. 
As we have previously reported, exercise reduced visceral adipose tissue in a dose-
response fashion (linear Ptrend=0.008), such that each 60 min·wk-1 increase in exercise 
volume predicted a –2.7±1.4 cm2 reduction in visceral adipose tissue [Brown et al].  For 
each 1 cm2 reduction in visceral adipose tissue, fasting insulin concentration was 
lowered by 0.96±0.41 pmol/L (P=0.025; Table 4.4, Figure 4.3) and changes in visceral 
adipose tissue accounted for 13.5% of the shared variance in changes in fasting insulin 
concentrations.  Changes in visceral adipose tissue also correlated with changes in 
fasting glucose and insulin resistance. 
Discussion 
A six month moderate-intensity aerobic exercise program among stage I-III colon cancer 
survivors reduced fasting insulin concentrations and insulin resistance in a 
predominately overweight and obese population.  The findings from this randomized trial 
support the hypothesis that the relationship between physical activity and colon cancer 
prognosis may be mediated, in part, by changes in fasting insulin concentrations or 
insulin resistance. 
The reductions in fasting insulin concentrations and insulin resistance with exercise are 
similar to those observed in a prior dose-response study in overweight and obese adults 
[Ross et al, 2015].  This study indicated that fasting insulin concentrations and insulin 
resistance may be lowered uniformly across distinct exercise doses in an L-shaped 
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pattern [Ross et al, 2015].  The absolute magnitude of reduction in fasting insulin 
concentrations in the current study was larger compared to other studies [Houmard et al, 
2004, Ross et al, 2015].  This may be the result of our sample having higher baseline 
fasting insulin concentrations (111 pmol/L vs 49 pmol/L [Houmard et al, 2004] and 67.5 
pmol/L [Ross et al, 2015]), which is consistent with a prior report that colon cancer 
survivors have significantly higher fasting insulin concentrations than matched healthy 
controls [Jiang et al, 2014].  Our findings are consistent with studies in breast cancer 
survivors that exercise reduces fasting insulin concentrations [Irwin et al, 2009, Ligibel et 
al, 2008]. 
In cross-sectional analyses, fasting insulin concentrations are higher with larger volumes 
of visceral adipose tissue, an effect that is attributable to increased insulin resistance 
[Goodpaster et al, 2003].  We demonstrated that changes in visceral adipose tissue 
account for only 13.5% of the shared variance in insulin concentration, consistent with a 
prior study in obese men that estimated the shared variance to be 22% [Rice et al, 
1999].  These data suggest that the effects of exercise to lower fasting insulin may 
include mechanisms beyond that of changes in visceral adipose tissue.  We hypothesize 
that alterations in skeletal muscle insulin resistance and free fatty acid (FFA) metabolism 
may help to further explain this effect [Abdul-Ghani and DeFronzo, 2010, DeFronzo and 
Tripathy, 2009].  Insulin resistance in skeletal muscle is associated with 
hyperinsulinemia [Abdul-Ghani and DeFronzo, 2010, DeFronzo and Tripathy, 2009], and 
the inability to lower FFA in the postprandial state [Jensen, 2008].  Skeletal muscle 
preferentially oxidizes FFA [Randle et al, 1963], suppressing insulin-stimulated glucose 
uptake into the muscle [Boden et al, 1994, Dresner et al, 1999].  Exercise improves the 
insulin suppression of FFA release [Shadid and Jensen, 2006], corrects the mismatch 
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between FFA uptake and FFA oxidation [Turcotte and Fisher, 2008], and promotes 
insulin-stimulated glucose uptake into skeletal muscle [Hayashi et al, 1997]. 
The biologic or biobehavioral pathways through which exercise may alter disease 
outcomes are unknown.  States of hyperinsulinemia activate the PI3K-Akt-mTOR 
pathway [McCurdy and Klemm, 2013].  In preclinical experiments, activation of the PI3K-
Akt-mTOR pathway promotes the growth of colon cancer metastases [Gulhati et al, 
2011], and inhibition of this pathway induces cell-cycle arrest and apoptosis [Zhang et al, 
2009].   Insulin receptor substrate 1 (IRS1) is a mediator of glucose homeostasis, and 
the down regulation of IRS1 is associated with insulin resistance [Karlsson and Zierath, 
2007].  Tumor expression of IRS1 and physical activity interact to influence colon cancer 
outcomes [Hanyuda et al, 2015].  Among patients with decreased expression of IRS1, 
physical activity is associated with a significant reduction in the risk of colon cancer-
specific mortality (Ptrend=0.005) whereas no relationship was observed with IRS2.  IRS1 
is associated with insulin metabolism in skeletal muscle, whereas IRS2 is associated 
with insulin metabolism in the liver [Karlsson and Zierath, 2007].  These observational 
data provide additional data to support the hypothesis that exercise may have an insulin 
sensitizing effect that is produced through skeletal muscle contractions, and this insulin 
sensitization may influence disease outcomes. 
There are several limitations to this trial.  The main limitation is the small size of the 
study sample which limits the generalizability of our findings.  We have previously 
demonstrated that participants in this trial were younger than the population from which 
they were recruited [Brown et al, 2016].  The small sample size precluded our ability to 
undertake formal mediation analysis to explore the relationships among exercise dose, 
insulin concentrations, and visceral adipose tissue [Friedenreich et al, 2011].  The small 
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sample size also limited our statistical power to examine other metabolic growth factors 
such as IGF-1.  Our study was only six months in duration.  It is unknown if the observed 
improvements in outcomes would be sustained or improved upon over a longer time 
horizon.  Participants were not recruited on the basis of having hyperinsulinemia; 
however 82% of our study sample was overweight or obese, consequently 
hyperinsulinemia was common.  We examined two distinct volumes of moderate-
intensity aerobic exercise, but we did not examine the effects of low-intensity aerobic 
exercise. 
There are several strengths to this trial.  The use of two intervention groups, each 
prescribed a distinct dose of exercise allowed us to examine changes in fasting insulin 
along the exercise dose curve.  The exercise program, which emphasized home-based 
treadmill walking, promoted good intervention adherence that was confirmed with 
objective heart rate monitor measures.  The majority of participants (97%) completed the 
study. 
In summary, the findings from this randomized dose-response trial demonstrate that 
moderate-intensity aerobic exercise reduces fasting insulin concentrations and insulin 
resistance among patients who have recently completed treatment for stage I-III colon 
cancer.  The findings from this randomized trial may be useful to help guide exercise 
prescriptions in this population.  The relationship between physical activity and colon 
cancer prognosis may be mediated, in part, by changes in insulin concentrations or 
insulin resistance.  Continued research to examine this hypothesis is warranted. 
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Table 4.1 Baseline characteristics of the participants  
Characteristic 
Total
(n=39) 
Control
(n=13) 
Low-Dose 
(n=14) 
High-Dose
(n=12) P
Age, years 56.5±10.0 57.9±9.7 58.2±9.8 53.1±10.5 0.493 
Sex, %      
Male 15 (38%) 4 (31%) 7 (50%) 4 (33%) 0.601 
Female 24 (62%) 9 (69%) 7 (50%) 8 (67%)  
Race, %      
White 31 (80%) 8 (62%) 12 (86%) 11 (92%) 0.332 
Black 6 (15%) 3 (23%) 2 (14%) 1 (8%)  
Other 2 (5%) 2 (15%) 0 (0%) 0 (0%)  
Education, %      
High School or Less 7 (18%) 1 (8%) 4 (29%) 2 (17%) 0.765 
Some College 8 (20%) 3 (23%) 2 (14%) 3 (25%)  
College Degree or More 24 (62%) 9 (69%) 8 (57%) 7 (58%)  
Smoking History, %      
Never 23 (59%) 10 (77%) 6 (43%) 7 (58%) 0.407 
Former 14 (36%) 3 (23%) 7 (50%) 4 (33%)  
Current 2 (5%) 0 (0%) 1 (7%) 1 (8%)  
Caloric Consumption, kcal·d-1 1747±542 1749±545 1816±569 1665±543 0.725 
Calories from Carbohydrate, % 45.6±8.8 45.0±10.6 46.6±7.3 45.2±9.2 0.701 
Moderate or Vigorous Physical 
Activity, min·d-1 
15.7±8.7 12.2±8.1 18.8±9.6 15.7±7.3 0.175 
Body Mass Index, kg·m-2 30.3±5.8 29.2±6.0 29.5±4.3 32.4±6.9 0.408 
Stage, %      
I 5 (13%) 1 (8%) 2 (14%) 2 (17%) 0.999 
II 14 (36%) 5 (38%) 5 (36%) 4 (33%)  
III 20 (51%) 7 (54%) 7 (50%) 6 (50%)  
Chemotherapy, % 28 (72%) 10 (77%) 10 (71%) 8 (67%) 0.906 
Time Since Treatment Completion, 
Months 
10.9±6.1 11.3±6.7 8.8±5.8 11.3±5.7 0.417 
ECOG Performance Status, %      
0, Fully active 29 (74%) 10 (77%) 9 (64%) 10 (83%) 0.595 
1, Ambulatory, but restricted in 
strenuous activity 
10 (26%) 3 (23%) 5 (36%) 2 (17%)  
Comorbid Conditions, %      
Hypertension 13 (33%) 4 (31%) 6 (43%) 3 (25%) 0.695 
Hyperlipidemia 6 (15%) 1 (8%) 2 (14%) 3 (25%) 0.480 
Type 2 Diabetes 5 (13%) 1 (8%) 1 (7%) 3 (25%) 0.409 
Cardiovascular Disease 4 (10%) 2 (15%) 1 (7%) 1 (8%) 0.827 
5-Year Predicted Survival, % 68 [60-87] 68 [61-85] 71 [60-88] 65 [60-83] 0.713 
P values are from the overall test of group differences.   
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Table 4.2 Exercise prescription program variablesa  
Characteristic 
Low-Dose
(n=14) 
High-Dose
(n=12) 
∆ Between Groups
(LS Mean ± SE) P
Frequency (days of exercise per week) 3.5±0.15 4.3±0.16 0.75±0.22 0.001 
Fractionization (sessions of exercise per 
day) 
1.1±0.07 1.4±0.07 0.31±0.10 0.001 
Intensity (% of heart rate maximum) 71.6±1.16 69.6±1.27 -1.89±1.72 0.272 
Time (minutes of exercise per day) 41.6±2.38 59.1±2.57 17.4±3.50 <0.001 
Type (% of exercise sessions using 
treadmill) 
72.3±12.9 81.3±15.5 8.0±18.71 0.669 
Volume (minutes of exercise per week) 141.5±9.92 247.2±10.71 105.7±14.60 <0.001 
Progression (weeks to full dose of 
exercise)b 
4 [4-5] 8 [7-10] 4 [2-6] 0.007 
% of exercise confirmed with HRM 97.3±0.81 96.2±0.87 -1.1±1.19 0.344 
% adherence to prescribed exercise 
dose 
92.8±2.44 89.0±2.64 -3.8±3.60 0.287 
% with ≥80% adherence, n (%) 12 (86%) 9 (75%) -10.6±15.2 0.488 
MET hours per weekc  13.7±0.96 23.9±1.03 10.2±1.41 <0.001 
aData are least squares mean (LS Mean) ± standard error (SE) unless otherwise noted. bMedian 
[interquartile 25-75% range]. cCalculated using available treadmill speed and incline, and averaged across 
all exercise sessions.   
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Table 4.3 Metabolic growth factor outcomes at baseline and change during six months 
Outcome 
Baseline
(Mean ± SD) 
∆ Baseline to Month 6
(LS Mean ± SE) 
∆ from Control
(LS Mean ± SE) 
Insulin, pmol/L 
Control 99.2±60.5 −7.36±9.41 — 
Low-Dose 101.8±40.5 −28.02±8.35a −20.66±12.58 
High-Dose 135.1±87.1 −20.70±9.35a −13.34±13.26 
Test for trend  Linear, P=0.170  
Nonlinear, P=0.042 
 
Glucose, mmol/L    
Control 5.3±1.0 0.01±0.16 — 
Low-Dose 5.3±0.8 −0.39±0.15a −0.39±0.22 
High-Dose 6.1±2.3 −0.09±0.17 −0.09±0.24 
Test for trend  Linear, P=0.931  
Nonlinear, P=0.004 
 
Insulin Resistance 
(HOMA)  
   
Control 2.2±1.3 −0.11±0.20 — 
Low-Dose 2.2±0.9 −0.63±0.17a −0.52±0.26b
High-Dose 2.9±2.0 −0.43±0.19a −0.32±0.27 
Test for trend  Linear, P=0.125  
Nonlinear, P=0.012 
 
IGF-1, nmol/L    
Control 58.0±15.9 −4.57±3.23 — 
Low-Dose 59.8±13.2 −0.94±3.21 3.63±4.55 
High-Dose 64.7±17.5 1.62±3.57 6.19±4.82 
Test for trend  Linear, P=0.054  
Nonlinear, P=0.850 
 
IGFBP-3, nmol/L 
Control 1765.1±446.8 −103.71±69.15 — 
Low-Dose 1925.7±449.5 −30.01±68.04 73.69±97.27 
High-Dose 2290.0±748.2 −154.28±71.97a −50.58±100.13 
Test for trend  Linear, P=0.685  
Nonlinear, P=0.093 
 
C-Peptide, nmol/L    
Control 0.64±0.4 0.007±0.033 — 
Low-Dose 0.58±0.3 −0.003±0.032 −0.010±0.046 
High-Dose 0.75±0.3 −0.013±0.035 −0.020±0.048 
Test for trend  Linear, P=0.701  
Nonlinear, P=0.934 
 
Fructosamine, mmol/L    
Control 201.4±20.5 2.60±16.82 — 
Low-Dose 183.0±51.2 22.91±15.84 20.31±23.11 
High-Dose 204.1±28.6 −12.65±16.96 −15.26±23.89 
Test for trend  Linear, P=0.380  
Nonlinear, P=0.382 
 
SD, standard deviation; LS Mean, least squares mean; SE, standard error; HOMA, homeostatic model 
assessment.  aSignifcantly different from baseline (within-group), P≤0.05. bSignificantly different from control, 
P≤0.05.   
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Table 4.4 Relationship between change in visceral adipose 
tissue (per 1 cm2 reduction) and change in metabolic growth 
factor concentration during six months 
Outcome 
∆ in Metabolic Growth 
Factor  Concentration 
(LS Mean ± SE) R2 P 
Insulin, pmol/L −0.96±0.41 13.5% 0.025 
Glucose, mmol/L −0.03±0.01 21.9% 0.004 
Insulin Resistance 
(HOMA) 
−0.024±0.009 16.5% 0.013 
IGF-1, nmol/L −0.22±0.13 7.6% 0.098 
IGFBP-3, nmol/L −1.22±3.16 0.4% 0.701 
C-Peptide, mmol/L 0.0007±0.001 0.6% 0.650 
Fructosamine, mmol/L −0.16±0.47 0.3% 0.736 
LS Mean, least squares mean; SE, standard error; R2, proportion of variability 
of change in metabolic growth factor concentration explained by change in 
visceral adipose tissue.  
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Figure 4.1 Flow of participants through the study 
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Figure 4.2 Between group changes in fasting insulin concentration from baseline to six 
months 
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Figure 4.3 Relationship between changes in visceral adipose tissue area and changes 
in fasting insulin concentration from baseline to six months  
-4
0
-2
0
0
20
40
  F
as
tin
g 
P
la
sm
a 
In
su
lin
 (p
m
ol
/L
)
LS
 M
ea
n 
  S
E
-30 -20 -10 0 10 20 30 Visceral Adipose Tissue Area (cm2)
 
 
 
 
 
β=0.96  
P=0.025 
R2=13.5% 
 100 
CHAPTER 5. CONCLUSIONS & FUTURE DIRECTIONS 
The purpose of this dissertation was to clarify how exercise may alter pathways that are 
hypothesized to influence disease outcomes among colon cancer survivors.  We also 
examined the generalizability of our study population to the broader population of colon 
cancer survivors.  The data gathered from this dissertation help to improve the specificity 
of exercise prescriptions provided to colon cancer survivors, strengthen the rationale that 
a causal relationship exists between exercise and disease outcomes, and refine key 
design aspects for future randomized trials in this population. 
Specific aim one sought to quantify and describe the dose-response effects of moderate-
intensity aerobic exercise on visceral adipose tissue (VAT).  We hypothesized that 
exercise would favorably reduce VAT in dose-response fashion.  Our hypothesis was 
supported as moderate-intensity aerobic exercise significantly reduced VAT in linear 
dose-response fashion (Ptrend=0.008).  Specific aim two sought to quantify and describe 
the dose-response effects of moderate-intensity aerobic exercise on levels of fasting 
insulin.  We hypothesized that exercise would favorably reduce levels of fasting insulin in 
dose-response fashion.  Our hypothesis was supported as moderate-intensity aerobic 
exercise significantly reduced levels of fasting insulin in nonlinear fashion (Ptrend=0.042).  
Specific aim three sought to quantify and describe demographic, clinical, and 
geographical characteristics associated with eligibility screening and study enrollment.  
We hypothesized that demographic, clinical, and geographical characteristics would be 
associated with eligibility screening and study enrollment.  Our hypothesis was 
supported as colon cancer survivors who were screened for eligibility and enrolled in the 
study were significantly younger (screening P<0.001, enrollment P=0.007) and more 
 101 
likely to have been treated with chemotherapy (screening P<0.001, enrollment P=0.006) 
than the population from which they were recruited. 
Since the initiation of the COURAGE trial, research has continued to accumulate that 
further strengthens the rationale and scientific basis for this line of inquiry.  
Epidemiologic data have provided additional evidence supporting the association 
between physical activity and disease outcomes among colon cancer survivors 
[Campbell et al, 2013] and these data have now been summarized in systematic reviews 
and meta-analyses that demonstrate a dose-response relationship between physical 
activity and outcomes [Je et al, 2013, Schmid and Leitzmann, 2014].  Molecular 
epidemiology studies have characterized tumor features that help to identify patients 
who may reap the largest cancer-specific benefits from exercise [Hanyuda et al, 2015, 
Yamauchi et al, 2013].  Preclinical models have provided important mechanistic data to 
guide clinical studies [Huffman et al, 2013].  Evidence continues to emerge that VAT and 
hyperinsulinemia are associated with disease recurrence and mortality among colon 
cancer survivors [Cakir et al, 2015, Devin et al, 2015]. 
Understanding how the dose of physical activity influences cancer prognosis is one of 
the most provocative unanswered questions in oncology [Lam et al, 2013].  The National 
Cancer Institute has expanded its funding portfolio to support research to answer this 
question [Alfano et al, 2016, Ballard-Barbash et al, 2013].  Elucidating if and how 
physical activity reduces the risk for cancer recurrence and/or improves survival is 
currently the #1 research question in the field of exercise-oncology [Courneya et al, 
2015].  The importance of this line of research has been echoed by various national 
organizations including the Institute of Medicine (IOM), American Society of Clinical 
Oncology (ASCO), American Association of Cancer Research (AACR), American 
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Society of Preventive Oncology (ASPO), and the American Cancer Society (ACS), as all 
of these organizations have hosted meetings with themes focused on energy balance, 
exercise, obesity, and lifestyle practices to promote healthy cancer survivorship.  Some 
organizations have published position papers from these meetings [Alfano et al, 2014, 
Demark-Wahnefried et al, 2012, Ligibel et al, 2014, Ligibel et al, 2015].  Given the recent 
surge of enthusiasm in this area, the findings from the COURAGE trial are timely, are of 
high interest to the clinical and research communities, and will provide important data to 
guide the field over the next decade. 
As described in Chapter 1, oncologists will continue to field questions such as “Should I 
exercise?  Should I lose weight?  What will improve my chances?” from the 83,000 
people who are diagnosed with non-metastatic colon cancer each year.  Oncology 
providers are uniquely positioned to offer guidance about exercise to patients.  Patients 
often view oncologists as decision-makers for their health, and the oncologist 
recommendation is possibly the biggest catalyst to initiate behavior change [Brown and 
Schmitz, 2014a].  Patients are likely to remember recommendations about physical 
activity from their oncologist if there is the perception that the provider values such 
behaviors.  A diagnosis of cancer is often viewed as a teachable moment where patients 
may be amenable to adopting recommendations about physical activity and other 
lifestyle behaviors, such as quitting smoking, losing weight, and improving their diet 
[Brown and Schmitz, 2014a].  Clinical practice guidelines encourage oncology providers 
to recommend that patients engage in a physically active lifestyle [Meyerhardt et al, 
2013].  After making this recommendation to patients, providers often field the follow-up 
question of “How much should I do?” or “How much is enough?”  The data generated 
from this dissertation begins to answer these questions.  The linear dose-response 
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reductions observed for VAT, and the nonlinear dose-response reductions observed for 
fasting insulin suggest that providers should encourage patients work towards the goal 
of 300 min·wk-1 as long as the provider believes it is safe to do so.  This 
recommendation is also grounded in behavioral science practices, wherein higher 
exercise goals result in more exercise completed, even if the goals themselves are not 
achieved [Hultquist et al, 2005, Perri et al, 2002]. 
These data are useful to begin to fill the developmental pipeline for binging exercise to 
the standard of clinical care for adjuvant colon cancer (see Figure 1.6 in Chapter 1).  
Recruitment, adherence, and follow-up are three critical aspects to success for any trial, 
particularly a behavioral trial such as COURAGE.  Perhaps the most novel feature of this 
trial was the provision of permanent in-home treadmills.  The purpose of providing in-
home treadmills was three-fold.  First, it served as a reasonable incentive for 
participation.  This effort was successful as recruitment was completed ahead of 
schedule.  Second, it was provided to promote high levels of exercise adherence.  This 
effort was successful as exercise adherence in the low-dose and high-dose groups were 
92% and 89%, respectfully.  The provision of a treadmill was cited by nearly every 
participant as being central to their exercise success and motivation to meet the study 
goals.  For example: “I feel blessed for that treadmill in my living room, I wouldn’t be this 
good with my exercise if I had to go outside all the time” [participant 025 in the low-dose 
group quoted at month 5 of the study.  This participant finished with 100% adherence] 
and “I feel like you have positioned me for lifelong success with this treadmill, knowing 
that you invested this much in me provided the motivation to do my exercise on the days 
I was feeling sluggish” [participant 016 in the high-dose group quoted at the end of the 
study.  This participant finished with 98% adherence]. Third, it provided an incentive for 
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control group participants to successfully complete the study.  This effort was successful 
as 12 of 13 control group participants, and all 26 participants in the two exercise groups, 
completed the trial (97% completion rate).  Although it is possible to conduct trials of 
exercise without providing in-home exercise equipment, the experience from this trial is 
consistent with the hypothesis that the provision in-home exercise equipment may 
improve recruitment, adherence, and follow-up.  If the principal goal of prescribing 
exercise to colon cancer survivors is to prevent disease recurrence, then an in-home 
treadmill is similar to durable medical equipment.  Future studies that provide in-home 
exercise equipment should aim to quantify the cost-effectiveness of such an approach.  
The treadmills provided in our study cost $1,000 per person.  The cost of treating 
recurrent colon cancer with palliative chemotherapy often exceeds $100,000 per person 
per year [Wong et al, 2009].  Empirical data that integrate costs, patient satisfaction, and 
the magnitude of health benefit will help to guide the development of interventions that 
are designed to succeed from a patient, provider, and third-party payor perspective 
when adopted into the standard of care for colon cancer. 
This area is rich with opportunities to understand how exercise can be used to promote 
healthy colon cancer survivorship.  This dissertation contributes to advancing that 
mission.  Additional data from future trials are urgently needed.  These additional data 
will allow for more definitive guidance to colon cancer survivors.  As described in 
Chapter 1, future studies should build upon this work by investigating the specific 
pathways through which exercise improves disease outcomes.  The collaboration of 
clinical and basic scientists will accelerate progress in this area [Gehlert et al, 2014].  
Future single-center studies should continue to monitor the safety and feasibility of 
exercise, while documenting the physiologic changes that are hypothesized to mediate 
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the relationship between exercise and disease outcomes. In the near future, multicenter 
feasibility trials will be necessary to increase sample sizes and commence a coordinated 
effort to improve efficiency and concentrate synergy.  The planning and design of these 
multicenter feasibility trials are of critical importance given that their purpose will be to 
establish a robust foundation on which to build definitive phase III trials. 
In conclusion, we have demonstrated that exercise induces several favorable 
physiologic changes among colon cancer survivors.  Such changes include reductions in 
VAT and reductions in fasting insulin concentration.  The participants in this trial were 
younger and more likely to have been treated with chemotherapy than the population 
from which they were recruited.  Disease recurrence is a formidable reality for many 
colon cancer survivors and presents a critical barrier to long term survivorship.  
Continued efforts to elucidate the biologic or biobehavioral pathways through which 
exercise improves colon cancer outcomes are necessary.  Generating the compendium 
of evidence that is sufficiently persuasive to shift clinical practice will be complex, time 
consuming, and undoubtedly encounter bumps in the process.  However, the 
satisfaction of empowering patients, families, and providers with practical evidence-
based solutions to reduce the risk of disease recurrence is well worth the necessary 
sacrifice. 
 
### 
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